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Abstract
Lutein (L) and zeaxanthin (Z) are nutrients that reduce the risk of age-related macular degeneration (AMD).
As micronutrients that selectively accumulate in the retina of the eye, L/Z can protect the macula from
oxidative damage that contributes to AMD. This review will discuss the role of genes as a mediator between
increased intake of dietary L/Z and decreased risk of AMD. Figure 1 outlines a pathway of L/Z that is subject
to genetic influences, from 1) the diet to 2) the bloodstream to 3) the retina of the eye. First, L/Z are
carotenoids that cannot be synthesized de novo and must be consumed from fruits and vegetables in the diet.
Secondly, L/Z are transported by high-density lipoproteins (HDL) in the blood to the retina. Genetic variants
that influence HDL status may impact the amount of L/Z that reaches retinal cells. Thirdly, L is taken up by
retinal cells. Intracellularly, L down-regulates the expression of proinflammatory genes that contribute to the
development of advanced AMD. Overall, L/Z are carotenoids in the diet that are transported by HDL and
affect inflammatory pathways in AMD. The intersection of dietary L/Z, genes, and AMD will be reviewed
using exemplary epidemiological, genome-wide association, and in vitro studies. The literature will support
the integration of personalized nutrition, or dietary recommendations based on genomic information, into the
field of eye care.
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Figure 1. The role of lutein (L) and zeaxanthin (Z) in the nutrigenomics of AMD. 
 
Lutein (L) and zeaxanthin (Z) are nutrients that reduce the risk of age-related macular 
degeneration (AMD). As micronutrients that selectively accumulate in the retina of the eye, L/Z 
can protect the macula from oxidative damage that contributes to AMD. This review will discuss 
the role of genes as a mediator between increased intake of dietary L/Z and decreased risk of 
AMD. Figure 1 outlines a pathway of L/Z that is subject to genetic influences, from 1) the diet to 
2) the bloodstream to 3) the retina of the eye. First, L/Z are carotenoids that cannot be synthesized 
de novo and must be consumed from fruits and vegetables in the diet. Secondly, L/Z are 
transported by high-density lipoproteins (HDL) in the blood to the retina. Genetic variants that 
influence HDL status may impact the amount of L/Z that reaches retinal cells. Thirdly, L is taken 
up by retinal cells. Intracellularly, L down-regulates the expression of proinflammatory genes that 
contribute to the development of advanced AMD. Overall, L/Z are carotenoids in the diet that are 
transported by HDL and affect inflammatory pathways in AMD. The intersection of dietary L/Z, 
genes, and AMD will be reviewed using exemplary epidemiological, genome-wide association, 
and in vitro studies. The literature will support the integration of personalized nutrition, or dietary 
recommendations based on genomic information, into the field of eye care.  
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Literature Review of Nutrigenomics of Age-Related Macular Degeneration 
 
Chapter 1. Introduction 
 
1.1 Age-Related Macular Degeneration 
 
Age-related macular degeneration (AMD) is an eye disease that causes irreversible loss 
of central vision.1 In the developed world, AMD is the leading cause of blindness among people 
of European ancestry aged 65 or older. AMD is particularly concerning to the healthcare system, 
given that its prevalence increases sharply after age 80.2 As the aging population of the US 
increases, the impact of AMD will also increase. In the United States alone, an estimated 3 
million people will have AMD by the year 2020.3 Worldwide, an estimated 288 million people 
will have AMD by the year 2040.4 For those affected, AMD has a profound effect on quality of 
life. Patients with vision loss from AMD have reported diagnoses of clinical depression and 
significant impairment in their abilities to participate in valued activities.3 The burden of AMD on 
patients demands more effective strategies to prevent both the onset and progression of AMD. On 
top of AMD’s devastating health effects on quality of life, the disease also has a costly financial 
impact on the economy. In 2012, the economic burden of advanced neovascular AMD and 
advanced dry AMD on the US gross domestic profit was estimated to be over $40 billion.5 The 
projected substantial global impact of AMD calls for a need to discover and implement new eye 
care strategies. 
 
Figure 2. Classifications of AMD. There are three main stages of AMD, each progressing in 
severity of vision loss.6 Early AMD is the first stage of AMD, intermediate AMD is the second 
stage of AMD, and advanced AMD is end stage macular degeneration. There are two types of 
advanced AMD: dry and neovascular (wet) AMD.  
 
As its name suggests, AMD is strongly associated with aging, and can be categorized into 
temporal stages. Figure 2 shows the three main stages of AMD, each increasing in severity of 
vision loss.6 The first stage of AMD is known as early AMD. Early AMD is characterized by the 
presence of soft drusen and pigment abnormalities in the retinal epithelium. Drusen are yellow 
deposits of waste products found under the retina. Retinal pigment abnormalities consist of either 
hyper- or hypo-pigmentation in retinal epithelial cells. Most patients do not experience vision loss 
with early AMD. Over time, early AMD may develop into intermediate AMD. Intermediate 
AMD is characterized by the presence of larger-sized soft drusen and retinal pigment 
abnormalities. Patients may experience some vision loss at this stage. In some cases, intermediate 
AMD further develops into advanced AMD. Advanced AMD can be either categorized as dry 
AMD or neovascular (wet) AMD. Dry AMD is characterized by atrophy of light-sensitive cells in 
the macula. Vision loss due to dry AMD is typically a gradual process occurring over a period of 
years. Neovascular AMD is characterized by the abnormal growth of weak blood vessels under 
Neovascular Dry 
Early  
AMD 
Advanced 
AMD 
Intermediate 
AMD 
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the retina, which can leak fluid and damage the macula. Vision loss due to neovascular AMD is 
typically a rapid process occurring over weeks or months. In clinical studies, AMD status is often 
classified by trained graders, using images of the retina that are captured by digital fundus 
photography.7 
Between the two subtypes of advanced AMD, the dry form is more common than the 
neovascular form. However, neovascular AMD is characterized by more rapid and severe vision 
loss.8 Due to its serious health implications, this review will primarily focus on the advanced, 
neovascular form of AMD. A major challenge of the current healthcare system is the pressure to 
meet the demands of long-term vision care in the elderly population. Even though neovascular 
AMD is rare, representing approximately 10% of AMD cases,9 its severity calls for the pursuit of 
new preventive strategies in order to avoid a large increase in cases of advanced AMD.  
One such strategy is personalized nutrition. Given that food is a consistent, readily 
available commodity in the developed world, targeting diet has the potential to prevent a large 
increase in prevalence of AMD. In applying personalized nutrition to AMD, clinicians use the 
unique genomic information of individual patients to make specific dietary recommendations that 
correlate with the greatest reduced risk of disease. As genetic testing becomes more accessible, 
the future of healthcare lies in personalized nutrition. A solid understanding of how genes may 
link diet to AMD is required in order to pinpoint nutrient intake levels that have the greatest 
protective effect. The literature presented in this review will show the importance of diet-gene 
interactions in the development of advanced AMD. Accordingly, this review will investigate the 
associations between advanced AMD, genetic makeup, and two micronutrients consumed in the 
diet.  
 
1.2 Introduction to Important Nutrients for AMD 
 
 Two micronutrients that are important in AMD are the carotenoids lutein (L) and 
zeaxanthin (Z). Notably, humans cannot synthesize carotenoids de novo, and must obtain L/Z 
exclusively from the diet.10 With respect to AMD, L/Z are important because they selectively 
accumulate in the macula, which is the region of the eye responsible for central vision.11 
Generally, higher concentrations of L/Z in the macula result in greater protection against 
oxidative damage that contributes to AMD.12 Thus, L/Z are often referred to as dietary macular 
carotenoids that have important roles in modulating AMD risk.13  
 
1.3 Carotenoids 
 
 Carotenoids are fat-soluble pigments synthesized by a variety of plants, resulting in the 
bright colors of fruits and vegetables.14 Structurally, carotenoids are tetraterpenoids that contain a 
central hydrocarbon chain of 40 carbons and end groups that are either cyclic or noncyclic.10 
Carotenoids can be divided into two major classes: carotenes and xanthophylls. Carotenes are 
reddish-orange pigments, chemically characterized by only carbon and hydrogen atoms. 
Xanthophylls are yellow pigments, chemically characterized by at least one oxygen atom. 
Examples of xanthophylls are the micronutrients lutein (L) and zeaxanthin (Z). Figure 3 depicts 
the chemical structures of L and Z.15 Both xanthophylls have a C40H56 central conjugated chain, 
and two hydroxyl groups. The presence of hydroxyl groups allow L/Z to have modestly better 
aqueous solubility than other carotenoids, which are typically very hydrophobic. Z also contains 
an extra conjugated double bond, which may lead Z to have different cellular effects as compared 
to L.  
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Importantly, animals and humans cannot synthesize carotenoids de novo.10 All 
carotenoids in the human body must come from dietary supply. 
 
 
 
 
 
 
 
Figure 3. Adapted from Woodall.15 Structures of the dietary macular carotenoids L and Z. 
Carotenoids are characterized by a core system of C40H56 conjugated polyene backbone chains 
(blue). L and Z both contain two hydroxyl groups, at the C-3 and C-3’ positions (green). L 
contains a double bond at the 4′, 5′ position (red, above), whereas Z contains a double bond at the 
5′, 6′ position (red, below).  
 
1.3.1 Lutein and Zeaxanthin 
 
Lutein (L) and zeaxanthin (Z) are the only dietary carotenoids found in eye tissues that 
are critical to vision.16 Therefore, L/Z were chosen for inclusion in this review because they are 
known to selectively accumulate in the macula of the eye.11 In the eye, the macula is a 6 mm 
region located in the central area of the retina that is responsible for high-acuity vision.17 Given 
that L/Z are obtained exclusively from the diet and compose pigment in the macula of the eye, 
L/Z are often referred to as dietary macular carotenoids.13  
L and Z are fat-soluble micronutrients belonging to the carotenoid family. As previously 
discussed, carotenoids are naturally occurring pigments found in almost all colored fruits and 
green leafy vegetables.18 Because humans do not synthesize carotenoids, L/Z must be consumed 
in the diet from sources such as spinach, peppers, and kiwi.11 Table 1 lists the concentrations of L 
and Z in commonly consumed fruits and vegetables. Notably, L is the predominant carotenoid in 
most of the listed foods. Green leafy vegetables are generally the richest sources of L. Also of 
particular interest is the wide variation of L/Z concentration in different cultivars of corn.19 Thus, 
there may be vastly different L/Z contents in different commercial varieties of the same plant. 
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Table 1. Adapted from Perry and Fanning.11,19 L and Z concentrations (μg/100 g) in fruits and vegetables.  
 Lutein (μg/100 g) Zeaxanthin (μg/100 g) 
Fruits 
Kiwi 171 0 
Grapes, green 53 6 
Grapes, red 24 4 
Apple, red delicious with skin 15 0 
Peach, raw 11 3 
Vegetables 
Spinach, raw 6603 0 
Broccoli, cooked 772 0 
Corn, Golden Sweet Improved 490 190 
Corn, White 30 30 
Lettuce, iceburg 171 12 
Artichoke heart 62 18 
Red Pepper 0 22 
 
1.4 Age-Related Eye Disease Study (AREDS): A Starting Point for Nutrient-AMD Link 
  
In 2001, the Age-Related Eye Disease Study (AREDS) was one of the first major clinical 
studies to suggest a link between micronutrients and AMD.20 As a large, interventional study 
conducted from 1992 to 2001, AREDS followed 3,540 participants aged 55 to 80 for an average 
of 6.3 years. At baseline, participants had either early AMD in at least one eye, intermediate 
AMD in at least one eye, or advanced AMD in one eye. To evaluate the effect of certain 
micronutrients on AMD progression, participants were assigned daily dietary supplements. These 
supplements were oral tablets that contained high doses of vitamin C, vitamin E, beta carotene, 
zinc, and copper. Participants were then examined annually for AMD. The results of AREDS 
showed that the combination of vitamins and minerals reduced the risk of progression to 
advanced AMD by 25%. Thus, AREDS provided the first evidence of the beneficial effects of 
nutritional supplements on advanced AMD. Unfortunately, AREDS was unable to observe any 
effects of L and/or Z because these carotenoids were not yet available in formulation at the time 
of this study. 
 Five years after the publication of AREDS, a follow-up study known as Age-Related Eye 
Disease Study 2 (AREDS2) was initiated.21 In AREDS2, the effects of L and Z were evaluated to 
understand whether these carotenoid pigments could further reduce the risk of AMD progression. 
From 2006 to 2012, AREDS2 followed 4,203 participants aged 50 to 85 for an average of 5 years. 
At baseline, participants had either intermediate AMD or advanced AMD in one eye. 
Interestingly, the results of AREDS2 suggested that adding both L (10 mg) and Z (2 mg) to the 
original AREDS formulation only reduced progression to advanced AMD in certain conditions. 
Specifically, the beneficial effects of supplemental L/Z were only observed in participants who 
originally consumed the lowest amounts of dietary L/Z, as well as in participants who received a 
formulation without beta carotene. Thus, AREDS and AREDS2 demonstrated that high doses of 
supplemental L/Z had limited beneficial effects against advanced AMD.   
In contrast to supplemental intake of L/Z in AREDS2, this review will focus on dietary 
intake of L/Z. Normal dietary levels of L/Z are generally much lower than the high dosages tested 
in AREDS2. To put the different L/Z contents in perspective, the L dosage in 10 mg of 
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supplemental L is equivalent to that in 1,295 g (approximately 6.4 cups) of cooked broccoli.11 
The Z dosage in 2 mg of supplemental Z is equivalent to that in 9,091 g (approximately 45 cups) 
of red pepper. Based on the Dietary Guidelines for Americans’s recommendation that nutritional 
needs should primarily be met through diet, studies investigating the effects of supplemental L/Z 
will be excluded.22 Accordingly, this review will focus on whether consumption of dietary 
sources of L/Z can be protective against advanced AMD. 
 
1.5 Genetic Factors of AMD 
 
Notably, genetic effects that may connect L/Z to AMD have not yet been extensively 
studied in humans. Potential genetic effects include variations in genotype and gene expression. 
Accordingly, this review will compile literature examining both directionalities of nutrient-gene 
interactions relating to AMD: 1) gene to nutrient (genotype) and 2) nutrient to gene (gene 
expression). Figure 4 shows a simplified pathway by which genotype and gene expression factor 
into the application of personalized nutrition to eye disease. In personalized nutrition, the unique 
genomic information of individuals can be used to customize dietary recommendations for the 
greatest reduced risk of eye disease. 
 
Figure 4. An overview of the application of personalized nutrition to eye disease.  
 
First, from gene to nutrient, an individual’s genotype may impact the body’s response to 
L/Z.23 Specific sets of genes direct specific metabolic processes, including the transport of L/Z to 
retinal cells, where greater accumulation of L/Z leads to greater protective effects against AMD. 
In particular, HDL (high-density lipoprotein) is important due to its role as the primary 
lipoprotein transporter of L and Z.24 Given that retinal cells are high in HDL receptors, there is 
preferential uptake of L/Z from HDL into the retina. However, different variants in HDL-related 
genes may change the efficiency by which L/Z undergo uptake and transport into the retina, thus 
modulating the risk of developing AMD.  
Secondly, from nutrient to gene, L/Z may regulate the expression of genes that contribute 
to AMD. Inside retinal cells, L/Z can decrease the concentration of genes and proteins involved in 
AMD pathogenesis. This review will focus on proinflammatory genes and proteins because the 
inflammatory response has been implicated as one of many possible pathways involved in AMD 
pathogenesis.25 Reactive oxygen species (ROS) have been found to upregulate proinflammatory 
pathways in the eye, causing morphological impairments to the RPE.26 Upon initial exposure to 
high-energy light, cells in the retinal pigment epithelium (RPE) become damaged.27 Damage to 
retinal cells then induces the production of ROS, such as superoxide anion (O2-), hydroxyl radical 
(OH•), hydrogen peroxide (H2O2), and singlet oxygen (1O2). In normal cellular metabolism, ROS 
are present at low concentrations and have beneficial effects. In conditions of oxidative stress, 
ROS are present at high concentrations and have deleterious effects. The highly reactive free 
radicals of ROS are known to damage cell structures, DNA, lipids, and proteins.28 The overall 
result of ROS accumulation is a chronic inflammatory response that exacerbates retinal damage, 
leading to advanced forms of AMD.25 Thus, the modulation of proinflammatory gene expression 
Nutrients 
Eye 
Disease 
Genotype 
Gene 
Expression    
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will be investigated because inflammation may contribute to the development of later stages of 
AMD.  
Both gene-to-nutrient and nutrient-to-gene interactions will be investigated to get a 
holistic understanding of the term “nutrigenomics”. Such interactions between L/Z and genes will 
also be discussed in the context of AMD pathogenesis to get a comprehensive understanding of 
nutrigenomics leading to the progression of neovascular AMD. 
 
1.6 Goals and Objectives 
 
The overall goal of this review is to demonstrate the effectiveness of personalized 
nutrition, specifically dietary L/Z, in preventing development of advanced AMD. To do so, the 
interactions between dietary levels of L/Z, genetic variation, and advanced AMD will be 
explored. Figure 5 presents a pathway showing how dietary L/Z could accumulate in the retina of 
the eye, where a high concentration of L/Z is protective, as well as two points in L/Z’s pathway at 
which genetic influences may inhibit development of advanced AMD. First, foods containing L/Z 
are consumed in the diet. L/Z are then released from food matrices and absorbed into the 
bloodstream. Coupled to HDL carriers in the blood, L/Z can then be transported to the eye. Here, 
genetic variants affecting HDL status may increase the efficiency of L/Z uptake into retinal cells. 
L/Z that are transported into the retina then selectively accumulate in the macula. Here, L may 
down-regulate the expression of inflammatory genes that contribute to AMD pathogenesis. 
Overall, dietary L/Z may prevent the development of advanced AMD through genetic effects 
related to HDL transport and inflammatory response. 
The objectives of this review are twofold: 1) to examine the clinical effects of dietary L/Z 
in development of advanced AMD, and 2) to compile current research supporting a role for 
genetics as a link between L/Z and advanced AMD.  
This review will take the form of a critical discussion that compares and contrasts 
different methodologies and arguments. Analyses of exemplary studies, promising research 
methods, and differing author opinions will be guided by a thesis arguing for the integration of 
personalized nutrition in eye care. To begin, epidemiological studies reporting associations 
between dietary L/Z and advanced AMD will be analyzed. Next, the interactions between L/Z 
and genetics will be examined from two aspects: genotype and gene expression. Genotype will be 
investigated by GWAS studies to understand how genetic variants related to HDL status 
influence the efficiency of L/Z transport to the retina, affecting susceptibility of developing 
AMD. Gene expression will be investigated by in vitro studies to understand how L may down-
regulate proinflammatory genes and proteins involved in AMD pathogenesis. Finally, the review 
will conclude by highlighting gaps in current research and future directions. Ultimately, this 
review will advance the field of eye care by advocating a unique approach to preventing 
development of advanced AMD from a personalized nutrition perspective.  
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Figure 5. An outline of the nutrigenomics of AMD. Increased levels of lutein (L) and zeaxanthin 
(Z) in the retina is protective. Foods containing L/Z are consumed (a) by an individual. L/Z are 
absorbed (b) and transported (c) to the eye. L/Z selectively accumulate in the macula (d), which is 
the central area of the retina that is damaged when an individual has AMD (e). Based on an 
individual’s genotype, genetic variants affecting HDL status may influence the efficiency of L/Z 
uptake into retinal pigment epithelium cells (f). Once inside retinal cells, L may down-regulate the 
expression of inflammatory genes that contribute to AMD pathogenesis (g).  
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Chapter 2. Epidemiological Studies Evaluating the Relationship Between L/Z and AMD 
Risk  
 
This review will first focus on human epidemiological studies reporting associations 
between dietary L/Z and advanced AMD. The literature as a whole shows that higher levels of 
dietary carotenoid intake are associated with a reduced risk for advanced neovascular AMD. 
Greater understanding of the extent to which dietary L/Z affects development of advanced AMD 
will justify the feasibility of dietary L/Z as a strategy to delay the progression of AMD. Table 2 
shows a compilation of the main results from epidemiological studies that will be discussed in 
detail in this chapter. 
 
2.1 Dietary L/Z and Advanced AMD 
 
2.1.1 Methodology 
 
Epidemiological studies can be categorized as cross-sectional or prospective. A cross-
sectional study is one type of epidemiology study that analyzes a population at a single point in 
time. The main advantages to cross-sectional studies are that they are less costly and can compare 
many different variables at one time to reveal correlations. Conversely, the main disadvantage to 
cross-sectional studies is that they cannot establish causal relationships.  
A prospective study is another type of epidemiology study that analyzes a population 
over an extended time period. The main advantages to prospective studies are that they can be 
tailored to collect specific data, and used to provide a timeline between exposure and onset of 
disease.29 However, the main limitation to prospective studies is the larger expense incurred over 
a long period of time. 
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Figure 6. Collection and analysis of data in epidemiological studies. 
 
Before comparing epidemiological studies, common methodologies used to collect and 
analyze clinical data will be discussed. Figure 6 depicts the general methodology for 
epidemiological studies, from A) data collection to B) data organization to C) data analysis. For 
data collection, dietary intake levels are commonly measured using food-frequency 
questionnaires (FFQs). FFQs are used to collect information on dietary habits by asking 
participants to note the type of food consumed, frequency of consumption, and/or portion size 
over a set period of time.30 Figure 6A depicts a population that is separated when individuals 
report distinct dietary habits on FFQs. Completed FFQs can then be used to generate intake 
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scores for various micronutrients, based on standard nutrient values derived from United States 
Department of Agriculture (USDA) sources.  
For epidemiological studies, FFQs are advantageous because they are a simple way to 
collect a large amount of individual data over an extended period of time. Additionally, the 
extended duration of data collection allows FFQs to account for wide day-to-day variations in 
nutrient intake. On the other hand, FFQs are disadvantageous because they may not accurately 
reflect specific types of foods consumed. The limited checklist of foods provided by FFQs will 
not completely match the exact types and prepared forms of foods consumed by participants. 
Recalling that different cultivars of plants may have vastly different L/Z contents19, the simplified 
list of foods on FFQs can lead to under- or over-estimations of nutrient values. 
To analyze the relationship between advanced AMD risk and L/Z nutrient levels, the 
generated nutrient scores derived from FFQs are typically categorized into tertiles, quartiles, or 
quintiles of intake. In other words, participants are split into three, four, or five groups based on 
how much L/Z they consume. Figure 6B depicts a population that is divided into five groups, 
from lowest L/Z intake (1st quintile) to highest L/Z intake (5th quintile). Odds ratios (ORs) are 
then calculated for each level of L/Z intake. Generally, ORs measure the association between an 
outcome and exposure.31 For the epidemiological studies included in this review, ORs reveal the 
odds of AMD occurring at each level of dietary L/Z intake. Figure 6C depicts the assignment of 
ORs to each group. As part of the analysis, either the highest or lowest level of dietary intake is 
set as a reference (OR = 1). The other levels of intake are then assigned OR values and compared 
to the reference. ORs > 1 indicate higher occurrence of AMD, and ORs < 1 indicate lower 
occurrence of AMD. For example, if the lowest dietary intake group is assigned as the reference 
(OR = 1), and higher dietary intake groups have OR values < 1, then the result indicates that 
increasing L/Z intake correlates with lower occurrence of AMD. In clinical research, ORs are 
particularly useful because they are simple measures that indicate what treatment has the best 
odds of improving a patient’s condition. 
 
2.1.2 Cross-Sectional Studies 
 
The published literature of relevant cross-sectional clinical studies has been controversial 
regarding the role of L/Z in AMD. Despite purported inconsistencies, a review of the data will 
reveal that dietary L/Z indeed has a protective role against advanced AMD. Three cross-sectional 
studies analyzing three separate populations will be presented. Two studies focused specifically 
on neovascular AMD, while one study did not differentiate between forms of advanced AMD. 
Prior to AREDS, evidence supporting the protective effect of L/Z on the neovascular 
form of advanced AMD was first reported in 1994.32 In a case-control study, Seddon aimed to 
evaluate the relationship between advanced AMD and intake of antioxidant nutrients in specific 
food items. As a medium-sized study, a total of 876 subjects from the Eye Disease Case-Control 
Study (EDCCS) were included. Three hundred fifty-six case subjects aged 55 to 80 who were 
diagnosed with advanced AMD were compared to 520 control subjects of the same age range and 
geographic areas.  
The overall results showed that higher levels of dietary carotenoid intake were associated 
with a reduced risk for neovascular AMD. In other words, there was a lower fraction of cases 
(with neovascular AMD) within the group consuming the greatest amount of total carotenoids, as 
compared to the fraction of cases in the group consuming the least amount of total carotenoids. 
Specifically, subjects in the highest quintile of total carotenoid intake (11,548 μg) were estimated 
to have a 43% decreased risk of AMD (OR = 0.57), as compared to the lowest quintile group 
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which was assigned a reference 0% decreased AMD risk (OR = 1). Notably, when L/Z were 
evaluated separately from beta-carotene, the highest quintile of L/Z intake (3455 μg) correlated 
with an even greater 57% decreased risk of AMD (OR = 0.43), suggesting that L/Z are the dietary 
carotenoids important for protecting against AMD. Similarly, when the effects of beta-carotene 
and L/Z were analyzed simultaneously, beta-carotene was only associated with a minor 9% 
reduced risk of AMD (OR = 0.91), whereas L/Z were strongly associated with a 56% reduced 
risk of AMD (OR = 0.44). The findings clearly indicated an inverse association between high 
dietary intake of L/Z and lower incidence of advanced neovascular AMD. 
As opposed to the results of Seddon’s case-control study, a cohort study published at the 
same time as AREDS reported no association between L/Z and advanced AMD.33 In this 2001 
cohort study, Mares-Perlman aimed to determine the relationship between dietary L/Z and 
advanced AMD. As a large study, a total of 8,244 participants from the Third National Health and 
Nutrition Examination Survey (NHANES III) were included.  
The overall results showed that there was no association between dietary L/Z and 
advanced AMD in the overall NHANES III sample. However, when subjects were stratified by 
age, conflicting results were observed. In the lowest age group of 60-79 years, subjects in the 
highest quintile of dietary L/Z intake had a significant 90% reduced risk of advanced AMD (OR 
= 0.1). On the other hand, for subjects aged 80 years and older, those in the highest L/Z quintiles 
had only a 40% reduced risk of advanced AMD (OR = 0.6). Mares-Perlman’s study concluded 
that most of the observed associations between dietary L/Z and advanced AMD were not 
significant, which directly contradicts Seddon’s results. However, specific subgroup analysis of 
people aged 60-79 years did show a significant protective effect of dietary L/Z on advanced 
AMD, which is consistent with Seddon’s results. 
The 2001 Mares-Perlman study differed from the 1994 Seddon study in terms of 
objective and participants. The sample size of Mares-Perlman’s study was more than 9-fold 
greater than that of Seddon’s study, suggesting that the results reported by Mares-Perlman were 
more reliable. However, the Mares-Perlman study’s observed lack of association between dietary 
L/Z and advanced AMD should not be interpreted as a blanket conclusion. Although the overall 
results concluded by Mares-Perlman and Seddon contrasted each other, the specific subgroup 
analysis of subjects aged approximately 60-80 years in fact support similar conclusions in both 
studies. Seddon’s analysis of 876 subjects aged 55-80 years and Mares-Perlman’s analysis of 
3,143 subjects aged 60-79 years supported a 57% and 90% reduced risk of AMD, respectively. 
As shown in Figure 7, both studies suggest that increasing L/Z intake in the diet can potentially 
protect against advanced forms of AMD, particularly in individuals aged 60-79 years. The 
difference in magnitude of effect could possibly be explained by the difference in race 
distribution of the participants. While Mares-Perlman included Blacks and Mexican Americans in 
their study, Seddon only analyzed White participants. Another possibility explaining variation in 
magnitude of effect is that Seddon looked specifically at one form of advanced AMD 
(neovascular AMD), while Mares-Perlman did not distinguish between the two forms of 
advanced AMD.   
11 
 
Figure 7. Cross-sectional studies point to an inverse association between dietary L/Z intake and 
advanced AMD. Participants aged 60-79 with high L/Z intake had lowest occurrences of advanced 
AMD, particularly the neovascular form. 
 
Further support for dietary L/Z’s protective role against advanced AMD was reported by 
Snellen in a 2002 small case-control study.34 Similar to Seddon’s case-control study, Snellen 
aimed to evaluate the relationship between dietary L/Z intake and the neovascular form of 
advanced AMD. A total of 138 subjects from the Netherlands were included in this smaller study. 
Seventy-two cases aged 60 years or older who were diagnosed with neovascular AMD were 
compared to 66 control patients. 
The overall results showed that lower intake of dietary carotenoid intake was associated 
with higher occurrence of neovascular AMD. Subjects in the lowest quartile of L/Z intake had 
double the prevalence rate of neovascular AMD (OR = 2.4), as compared to the prevalence rate of 
patients in the highest quartile of L/Z intake (OR = 1). Thus, Snellen’s results further bolster the 
suggested protective effects of L/Z against advanced AMD, and against neovascular AMD in 
particular.  
It should be noted that Snellen’s methodology of data collection differed from that used 
by Seddon and Mares-Perlman. Instead of using FFQs, subjects were verbally interviewed about 
their dietary habits and their intakes of fruits and vegetables. The method of using a verbal 
interview was advantageous because it removed possible misreading of questions, as patients 
with AMD had poor visual acuity and may not have been able to correctly read FFQs. However, 
introducing an interviewer into the methodology of data collection could have potentially altered 
the subjects’ answers, especially given that interviewers were not blind to the subjects’ disease 
statuses. Analysis of L/Z intake levels were also performed slightly differently than either Seddon 
or Mares-Perlman. Whereas the previous studies used standard nutrient values derived from the 
USDA, Snellen used L/Z values derived from the carotenoid database generated by Mangels in 
1993.35 Given that the USDA Nutrient Database is more recent and contains L/Z values for a 
greater variety of foods, USDA nutrient values are likely more reliable than nutrient values 
derived by Mangels’s original 1993 carotenoid database. Despite differences in data collection, 
Snellen’s small-scale study supported the results of Seddon and Mares-Perlman’s large-scale 
studies. 
 
2.1.3 Prospective Studies 
 
The published literature of relevant prospective clinical studies have been partly 
inconsistent regarding the role of dietary L/Z in AMD. Interestingly, some purported 
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contradictory results have been drawn from the same population cohort that was simply followed 
over different lengths of time. Given that AMD has distinct early and late stages, understanding 
the etiology of advanced AMD also requires understanding of its preceding stages. On the 
surface, discussing studies that focus on earlier stages of AMD seems to contradict the purpose of 
this review. However, the inclusion of early and intermediate AMD here will help clarify how 
high dietary L/Z is associated with less incidences of advanced AMD. As shown in Figure 8A, 
there are two phases in the development of advanced AMD at which L/Z could decrease the final 
number of advanced AMD cases. That is, does dietary L/Z correlate with lower occurrences of 
advanced AMD by preventing the initial occurrence of early AMD, or by preventing the 
progression of initial stages of AMD to advanced AMD?  
To help answer this question, the four prospective studies presented will represent two 
population cohorts followed over different periods of time. One population cohort was examined 
for early AMD and advanced AMD, while the other population cohort was analyzed for early 
AMD, intermediate AMD, and advanced AMD. Specific analyses both within the same 
population cohort and between different cohorts will reveal that dietary L/Z has a protective role 
against progression to the advanced stage of AMD. 
 
A 
B 
Figure 8. Prospective studies point to a protective role for dietary L/Z against the progression of 
early AMD to advanced AMD. (A) Without dietary L/Z, there is uninhibited onset of early AMD, 
and uninhibited progression of early AMD to advanced AMD. (B) With dietary L/Z, L/Z may 
delay the progression of early AMD to advanced forms. L/Z may also be weakly protective against 
onset of early AMD within a certain range of intake. 
  
The first population discussed here is the Blue Mountains Eye Study (BMES) cohort. In a 5-
year study, Flood aimed to evaluate the relationship between dietary L/Z intake and incidence of 
early AMD.36 From 1992 to 1994, a baseline total of 3654 BMES participants in Australia were 
examined. Five years later, from 1997 to 1999, 2335 of the original participants were reexamined. 
 The overall result showed that there was no association between baseline dietary L/Z 
intake and the 5-year incidence of early AMD in the BMES population. Although 192 
participants (8.2% of the follow-up sample) were observed to develop early AMD after 5 years, 
L/Z intake did not appear to be a protective or risk factor into the 5-year incidence of early AMD. 
The lowest and highest L/Z intake quintiles both had ORs of 1.0, indicating that L/Z intake did 
not reduce risk of early AMD.  
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 However, when the BMES participants were followed-up after an additional 5 years, an 
inverse association between L/Z intake and AMD was in fact observed. In this follow-up study, 
Tan aimed to elucidate the long-term risk of AMD by evaluating the effect of dietary L/Z intake 
on both early and advanced AMD.37 As continuation from the BMES study, 1952 participants 
(53.4% of the original 3654-person cohort) were reexamined after a total of 10 years. 
 Analysis of dietary L/Z intake levels was performed differently in Tan’s 2008 study. 
Instead of calculating ORs for each L/Z intake level, risk ratios (RRs) were calculated. RRs are 
inherently different from ORs in that RRs measure a ratio of probabilities, whereas ORs measure 
a ratio of an event to a nonevent.38 RRs should be interpreted as increased risk of disease (RR > 
1) or decreased risk of disease (RR < 1) among persons who have been exposed (to a certain level 
of dietary L/Z intake), relative to the control group.  
 Interestingly, the early AMD results from the 10-year BMES seemed to contradict those 
of the 5-year BMES. The 10-year BMES showed that above-median L/Z intakes were associated 
with reduced risk of early AMD. In contrast, the 5-year study reported no overall association. 
However, combining levels of L/Z intake between the 5-year and 10-year studies showed that 
although too much or too little L/Z intake has no effect, there may be an optimal range at which 
L/Z intake is protective against early AMD. In the 5-year study, there was no difference in OR 
between the top L/Z intake quintile (1466 μg) and the bottom L/Z intake quintile (288 μg), 
suggesting that the highest and lowest extremes of L/Z intake had no effect on risk of early AMD. 
Yet, the third (733 μg) and fourth (967 μg) L/Z intake quintiles did show some reduced risk of 
early AMD (OR = 0.8 and OR = 0.7, respectively). Similarly, the 10-year study observed that 
daily L/Z intakes of more than 743 μg were associated with some reduced risk of early AMD (RR 
= 0.66). As depicted in Figure 8B, the combined results of the 5-year and 10-year BMES studies 
indicate that at specific L/Z intake levels between 733 μg and 1466 μg, L/Z may be weakly 
protective against onset of early AMD.  
The advantage of the 10-year BMES study was its ability to follow the development of 
advanced AMD, in addition to early AMD. When participants were tracked for 10 years instead 
of 5 years, the highest tertile of L/Z intake (at least 942 μg/day) was associated with reduced risk 
of advanced AMD (RR = 0.72). Even more significantly, the highest L/Z intakes were associated 
with reduced risk of the neovascular form of advanced AMD (RR = 0.37). The strong association 
between dietary L/Z and neovascular AMD observed in the 10-year BMES is consistent with the 
results of cross-sectional studies. Moreover, the fact that dietary L/Z intake was more strongly 
associated with advanced neovascular AMD (RR = 0.37) than with early AMD (RR = 0.66), 
suggests a protective role for dietary L/Z in AMD progression rather than AMD initiation. Figure 
8B depicts the effects of dietary L/Z on development of AMD, showing that L/Z may have a 
stronger effect on inhibiting progression to advanced AMD than on inhibiting initiation of early 
AMD.  
Further support for dietary L/Z’s beneficial effect was later reported in a large-scale study 
that followed a different population cohort over an even longer duration of time. The second 
population discussed here is the combined Nurses' Health Study (NHS) and Health Professionals 
Follow-Up Study (HPFS) cohort. In an 18-year cohort study, Cho aimed to assess the effect of 
dietary L/Z intake on both early and advanced AMD.39 Thus, the objective of this 18-year 
NHS/HPFS study was similar to that of the 10-year BMES study, in terms of evaluating both 
early and late stages of AMD. From 1984 to 2002, a total of 71,494 women from NHS and 
41,564 men from HPFS were studied. At baseline, all participants were 50 years or older, and had 
no diagnosis of AMD.  
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Concerning advanced AMD, the overall result showed that L/Z intake had a possible 
inverse association with advanced neovascular AMD in the NHS/HPFS populations. For the 442 
participants who were observed to develop neovascular AMD after 18 years, increased L/Z intake 
appeared to be weakly associated with reduced risk neovascular AMD (RR = 0.72). When 
comparing the L/Z intake levels in the NHS/HPFS cohort versus those of the BMES cohort, the 
L/Z intakes in NHS/HPFS were generally much higher. The lowest quintile intake was 1390 
μg/day for NHS/HPFS, as compared to the much lower 288 μg/day lowest quintile intake for 
BMES. The highest quintile intake was 5320 μg/day for NHS/HPFS, as compared to the much 
lower 1466 μg/day highest quintile intake for BMES. Likely, the high L/Z intakes of NHS/HPFS 
reflect the generally healthier lifestyle of the study’s participants, who were all health care 
professionals. It is possible that the NHS/HPFS study may have had a ceiling effect, in which 
most participants consumed significant amounts of L/Z so there was not much room to observe 
the effects of very high or very low L/Z intake. Nonetheless, the collective results of NHS/HPFS 
and BMES so far suggest that over a wide range of L/Z levels, L/Z may have a protective effect 
against advanced neovascular AMD.  
Concerning early AMD, the overall result of the NHS/HPFS study showed that L/Z 
intake had no association with early AMD, similar to BMES’s result. Although 673 participants 
were observed to develop early AMD, L/Z intake did not appear to be a protective or risk factor 
into the 18-year incidence of early AMD. Specifically, NHS/HPFS’s observed lack of association 
between L/Z intakes of more than 1350 μg/day and risk of early AMD is consistent with BMES’s 
observed lack of association between L/Z intakes of 1466 μg/day and early AMD. Thus, the 18-
year NHS/HPFS further supported BMES’s finding that at high levels of L/Z, there is no 
association with early AMD.  
Generally, the 18-year NHS/HPFS study drew similar conclusions to the collated BMES 
studies. Both prospective studies suggested that L/Z intake was overall not associated with early 
AMD, but may be inversely associated with neovascular AMD. This conclusion further supports 
a protective role for L/Z against AMD progression but not initiation. Figure 8B shows that L/Z 
has a greater role in inhibiting progression to advanced AMD than in inhibiting onset of early 
AMD.  
When the participants of the NHS/HPFS study were followed-up after another 8 years in 
a different report, similar results were observed. In a 26-year prospective study of the same 
NHS/HPFS cohort, Wu sought to assess the association between dietary L/Z intake and AMD, 
with a distinct focus on intermediate and advanced AMD.40 As continuation from the NHS/HPFS 
study, 63,443 women from NHS and 38,603 men from HPFS were reexamined after another 8 
years. Notably, the analysis of L/Z intake scores differed from the previous 18-year study. In this 
study, dietary L/Z intakes were converted into predicted plasma levels of L/Z. The main 
advantage to plasma L/Z levels are that they reflect the bioavailable levels of L/Z in foods. 
Bioavailability refers to the proportion of ingested L/Z that is delivered to the bloodstream.41 The 
absolute amount of L/Z in foods may not equal the amount of L/Z that is ultimately absorbed into 
the bloodstream, due to limiting factors such as physical containment in the food matrix, 
interaction with dietary fat, and malnutrition. Therefore, L/Z levels calculated directly from FFQs 
may not adequately represent biologically relevant dosages.  
Consistent with the results of the 18-year NHS/HPFS study, the extended 26-year follow-
up indicated that L/Z intake had a possible inverse association with advanced neovascular AMD. 
During the additional 8 years of follow-up, an extra 676 advanced AMD cases, for a total of 1118 
cases, were reported. The addition of a large number of AMD cases provided a larger sample size 
that gave more reliability to the observed inverse association between L/Z and advanced AMD. 
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The highest quintile of plasma L/Z level was found to be associated with a 41% decreased risk of 
advanced AMD (RR = 0.59). Thus, higher intake of bioavailable L/Z was associated with a long-
term reduced risk of advanced neovascular AMD. 
In contrast, L/Z intake was not associated with intermediate AMD. For the 1361 
participants who were observed to display intermediate AMD after 26 years, the highest quintile 
of plasma L/Z level did not appear to be related to occurrence of intermediate AMD (RR = 0.93). 
This finding of a lack of association with intermediate AMD further supported the suggested 
mechanism of L/Z’s protective effect. Based on the two NHS/HPFS studies and two BMES 
studies, the lack of association with both early and intermediate AMD advocate a protective role 
for dietary L/Z in AMD progression rather than initiation. As depicted in Figure 8B, these studies 
suggest that L/Z may not prevent the onset of early AMD, but may delay the development of 
early AMD to advanced AMD. 
 
2.1.4 Evaluation of Epidemiological Results 
 
A major limitation of cross-sectional and prospective studies is that they can only 
establish correlations, and not causality. In other words, the observed inverse correlation between 
increased dietary L/Z intake and reduced cases of advanced AMD does not imply that L/Z has a 
direct protective effect. For example, there may be more people with AMD in the group 
consuming the lowest quintile of L/Z simply because people with macular degeneration eat fewer 
fruits and vegetables due to the difficulty of preparation. Similarly, people diagnosed with AMD 
may have selectively recalled worse dietary habits than controls, highlighting a psychological 
error inherent to the recall method of FFQs. Consequently, it would be reasonable to err on the 
side of caution when accepting these studies’ results about the protective effects of L/Z.  
However, support for L/Z’s direct involvement in reducing risk of AMD has been shown 
in studies that investigated macular pigment optical density (MPOD), in addition to L/Z intake 
and AMD incidence. MPOD reflects the concentration of L/Z in the macula.42 Given that higher 
levels of L/Z in the macula protects cells against oxidative damage, higher MPOD values are 
expected to be associated with reduced AMD risk if L/Z directly modulates AMD development. 
Indeed, these MPOD studies showed that the quantity of consumed L/Z determines MPOD, and 
that high MPOD was associated with reduced risk of AMD.43-45 Thus, MPOD results provide 
evidence that the observed correlations between dietary L/Z and AMD does in fact directly 
involve L/Z. 
 
2.1.5 Conclusion 
 
Overall, the cross-sectional and prospective studies reported here suggest that dietary L/Z 
may reduce the development of advanced neovascular AMD. Table 2 shows a compilation of the 
main results from these epidemiological studies. Although various studies found contradictory 
associations between L/Z and AMD, normalizing for the factors of age, level of L/Z intake, and 
type of AMD produced more consistent results. Based on two case-control studies, the 1994 
Seddon and 2002 Snellen studies, high dietary L/Z was found to be associated with reduced risk 
of the neovascular form of advanced AMD. The purported beneficial effect of dietary L/Z was 
further refined by age, in Mares-Perlman’s 2001 cross-sectional cohort study. Only in the 
subgroup of participants aged 60-79 years was high dietary L/Z intake correlated with lower risk 
of advanced AMD. Given that advanced AMD develops rapidly after age 80, dietary L/Z may 
16 
 
only be protective in relatively younger persons who have not yet progressed past the initial 
stages of advanced AMD.  
 More recently, prospective studies have further supported the protective role of dietary 
L/Z. Starting in 1984, the NHS/HPFS populations were followed for 18-years and 26-years by 
two separate studies. Concurrently, starting in 1992, the BMES population was followed for 5-
years and 10-years by two separate studies. Concerning early AMD, both BMES studies 
suggested a weak association between dietary L/Z and early AMD, but only within a certain L/Z 
intake range between 733 μg/day and 1466 μg/day. Concerning intermediate AMD, the 26-year 
NHS/HPFS study found no association. Concerning advanced AMD, both the 10-year BMES 
study and 26-year NHS/HPFS study observed strong inverse associations between dietary L/Z 
and neovascular AMD. Altogether, dietary L/Z intake was more strongly associated with 
advanced neovascular AMD than with either early AMD or intermediate AMD. Therefore, 
dietary L/Z is likely only protective against the progression of AMD to its advanced stage, and 
not protective against the initial occurrence of early AMD. 
 
Figure 9. Personalized nutrition: Linking nutrition to eye disease. Dietary L/Z is a feasible 
strategy to delay the progression of advanced AMD. 
 
In the context of personalized nutrition, the results of these epidemiological studies justify the 
feasibility of dietary L/Z as a strategy to delay the progression of AMD. Figure 9 depicts the 
pathway by which personalized nutrition is applied to eye disease, highlighting a link between 
nutrient intake and advanced AMD. Observed associations between high L/Z intake and reduced 
risk for advanced AMD suggest that nutritional recommendations are, in fact, applicable to the 
field of eye care. Notably, different studies investigating different populations found that L/Z may 
be beneficial at different levels of intake. Thus, how can eye care providers make dietary 
recommendations that will lead to the best outcome (such as no incidence of advanced AMD) for 
each individual patient? One approach is to incorporate genomic information, in a strategy known 
as personalized nutrition. Moving forward, the function of genes as a link between L/Z intake and 
AMD risk will be discussed.
Nutrients 
Eye 
Disease 
Genotype 
Gene 
Expression    
Dietary L/Z Advanced AMD 
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Table 2. Epidemiological studies investigating the association between dietary L/Z intake and AMD.32-34,36,37,39,40 
Cross-Sectional Studies 
Reference Study Design Health Status Population 
Cohort 
Participants Age 
Range 
Range of 
L/Z Intake 
Results 
Seddon32 Cross-sectional 
case-control 
Advanced AMD EDCCS 356 cases 
520 controls 
55 – 80  336 μg – 
3,455 μg 
Increased LZ intake associated 
with reduced risk for AMD 
Mares-Perlman33 Cross-sectional Advanced AMD NHANES III Total 8,222  40 – 80+  315 μg – 
9,715 μg 
Dietary LZ was unrelated to 
AMD 
Snellen34 Cross-sectional 
case-control 
Advanced AMD NA 72 cases 
66 controls 
60+  NA Lower LZ intake associated with 
higher occurrence of neovascular 
AMD 
Prospective Studies 
Reference Study Design Health Status Population 
Cohort 
Participants Age 
Range 
Range of 
L/Z Intake 
Results 
Flood36 Prospective  
(5 yrs) 
Early AMD BMES Total 3,654  49 – 80+  288 μg – 
1,466 μg 
Dietary LZ was unrelated to 
incidence of early AMD 
Tan37 Prospective  
(10 yrs) 
Early + 
Advanced AMD 
BMES Total 3,654 49 – 80+ NA Increased LZ intake may reduce 
risk of advanced AMD  
Cho39 Prospective  
(18 yrs) 
Early + 
Advanced AMD 
NHS & HPFS Total 113,058 50+ 1,349 μg – 
5,712 μg 
Dietary LZ was unrelated to 
AMD  
Wu40 Prospective  
(26 yrs) 
Intermediate + 
Advanced AMD 
NHS & HPFS Total 102,046 50+ 1,848 μg – 
5,468 μg 
Increased LZ intake may reduce 
risk of advanced AMD only 
NA = not available.  
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Chapter 3. Clinical Studies Demonstrating a Genetic Basis for AMD 
 
Investigating the nutrigenomics of AMD warrants the question: is there even a genetic 
basis for AMD? If AMD is not hereditary, it would seem frivolous to review the relationship 
between dietary L/Z and genes related to AMD pathogenesis. Furthermore, application of 
personalized nutrition to eye disease demands that genes are in some way involved in modulating 
AMD risk.  
Table 3 summarizes the results of clinical studies supporting a substantial genetic 
contribution to AMD that will be discussed in detail in this chapter. A review of the literature that 
specifically investigates the heritability of AMD is surprisingly limited and non-recent. Despite 
the relative scarcity of heritability studies, all results point to at least some heritability for AMD. 
As such, this section will present early first-degree relative studies and twin studies which argue 
in favor of a genetic basis for AMD. Two exemplar first-degree relative studies and two exemplar 
twin studies are chosen for inclusion here because they are the most current studies that use 
similar methods of analyses. 
 
3.1 First-Degree Relative Studies 
 
Two first-degree relative studies support a genetic component in the incidence of 
advanced AMD, as shown in Table 3. In 1997, Seddon aimed to determine whether advanced 
AMD aggregates in families.46 To evaluate the familial contribution of AMD, this study 
compared the prevalence of any AMD in relatives of case subjects with advanced AMD to the 
prevalence of any AMD in relatives of control subjects without AMD. A total of 177 first-degree 
relatives of 119 cases, were compared to 146 first-degree relatives of 72 controls. ORs were 
calculated to determine whether relatives of cases had increased risk of AMD compared to 
relatives of controls. 
 The results of this first-degree relative study revealed that advanced AMD does have a 
familial component. Figure 10 shows that a higher percentage (23.7%) of case relatives reported 
having AMD, compared to only 11.6% of control relatives reported having AMD. Thus, the 
prevalence of AMD was significantly higher in relatives of cases than controls (OR = 2.4). When 
looking specifically at the neovascular form of AMD, the prevalence was even higher. 26.9% of 
the relatives of case subjects with neovascular AMD reported AMD (OR = 3.1), indicating that 
relatives of neovascular cases had a 3-fold increased risk of developing AMD. Overall, the 
prevalence of AMD was highest among first-degree relatives of cases with advanced neovascular 
AMD. This suggests that advanced AMD does have a familial component, whether the 
contribution be from genetic or shared environmental factors, or both. As such, the extent of 
genetic contribution remained to be investigated. 
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Figure 10. First-degree relative studies point to a genetic component for AMD. An orange figure 
represents an individual with AMD, and a gray figure represents an individual without AMD. 
There is greater prevalence of AMD among relatives of persons with AMD (23.7%) than among 
relatives of persons without AMD (11.6%). 
 
Consequently, one year later, Klaver sought to investigate to what extent advanced AMD 
is genetically determined.47 In 1998, Klaver used a familial aggregation study using the same 
methodology as Seddon. In this study, 186 first-degree relatives of 87 cases with advanced AMD, 
were compared with 343 first-degree relatives of 135 controls without AMD. The sample sizes 
used here were comparable to those in Seddon’s study. However, analysis of AMD risk in this 
study was more comprehensive. In addition to ORs, Klaver calculated RRs, lifetime risks, and 
population-attributable risks to achieve a more complete analysis of the genetic contribution to 
AMD.  
 The results of this first-degree study supported the findings of Seddon. The prevalence of 
AMD was significantly higher in relatives of cases with advanced AMD (OR = 19.8). The 
lifetime risk of advanced AMD was estimated to be 50% for case relatives, which was 
significantly higher than the 12% risk for control relatives (RR = 4.2). The population-attributable 
risk, which estimated the proportion of advanced AMD attributable to a genetic factor in the total 
population, was determined to be 23%. Thus, this study concluded that approximately one quarter 
of all advanced AMD was genetically determined. Overall, the two familial aggregation studies 
suggested that genetics indeed plays an important role in the pathogenesis of advanced AMD. 
 
 
 
Case Relatives 
Cases (with AMD) Controls (without AMD) 
Control Relatives 
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3.2 Twin Studies 
 
The twin studies presented here offer insight into the relative contributions of both 
genetic and environmental factors to AMD. Two twin studies support genetics as having a larger 
contribution to incidence of AMD than environmental factors, as shown in Table 3.  
In 2003, a twin study performed by Grizzard aimed to use concordance rates to evaluate 
the genetic contribution in AMD.48 A total of 25 twin pairs aged 63 to 85 years were included. 
This age range places the twin participants at high risk of developing AMD. Fifteen pairs were 
monozygotic (MZ) and 10 pairs were dizygotic (DZ). To analyze genetic contribution, each twin 
pair was assigned to one of the three classifications shown in Figure 11. Twin pairs were 
classified as either concordant (both twins have AMD, in a similar stage), intermediate (both 
twins have AMD, but in different stages), or discordant (one twin has AMD and the other twin 
does not have AMD).  
 
Concordant Intermediate Discordant 
 
 
 
 
 
 
 
 
 
 
Figure 11. Classification schemes for concordant, intermediate, and discordant twins. Twins 
classified as concordant both have similar types of AMD. Twins classified as intermediate have 
different types of AMD. A twin pair classified as discordant contains one twin with AMD and one 
twin without AMD. 
 
The overall results suggested that there is a genetic component to AMD. On average, 
around 11 of the 15 (73%) MZ pairs were classified as concordant, and none (0%) were classified 
as discordant. Of the 10 DZ pairs, only one was classified as concordant (10%), and an average of 
five (50%) were classified as discordant. Given that the majority (73%) of MZ pairs were 
concordant, and only one (10%) DZ pair was concordant, there appeared to be a significant 
positive association between monozygosity and concordance for AMD. 
Ultimately, this study suggested that genetics appears to play an important role in the 
etiology of AMD. However, this study did not differentiate between early and advanced AMD, 
nor did it quantify the genetic influence on AMD. 
Two years later, Seddon aimed to calculate the impact of genetic and environmental 
factors on AMD.49 In 2005, Seddon published a twin study that quantified the genetic influence 
on AMD and specified the heritability of the advanced stage of AMD, in particular.49 In this study 
a total of 391 twin pairs aged 78 to 88 years, along with 58 singletons, were included. This age 
range places the participants at high risk of developing advanced forms of AMD. 210 pairs were 
MZ and 181 pairs were DZ.  
The overall results suggested that AMD has a large genetic component, especially the 
advanced forms. When looking at concordance rates, 55% of MZ pairs were concordant for 
     
Advanced AMD Advanced AMD Advanced AMD Early AMD Advanced AMD No AMD 
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intermediate and advanced AMD, as compared to only 25% concordance in DZ pairs. These 
concordance rates differ from Grizzard’s 73% MZ concordance and 10% DZ concordance, which 
is expected given the large differences in sample size and cohort demographics. Nonetheless, 
both studies show that MZ twins display higher concordance of AMD than DZ twins. The 
relatively higher concordance in MZ twins supports a genetic contribution to AMD. Figure 12 
depicts the observed concordance rates for advanced AMD, specifically. When focusing on the 
advanced forms of AMD, concordance rates were 18% in MZ twins and 6% in DZ twins. Once 
again, the relatively higher concordance in MZ twins suggests a genetic component for advanced 
AMD.  
 
Monozygotic Twins 
 
Dizygotic Twins 
 
 
Figure 12. Concordance rates in twins point to a genetic component for advanced AMD. There is 
higher concordance of advanced AMD in MZ twins (18%) than DZ twins (6%). 
 
In addition to confirming that genes are involved in incidence of AMD, this study was 
notable for also quantifying the relative contributions of genes and the environment on AMD. 
Heritability was estimated to be 0.46 for any AMD and 0.71 for advanced AMD, suggesting 
higher heritability of advanced forms. Environmental factors unique to each twin were estimated 
to explain between 19% and 37% of the variation in AMD stage. Overall, genetic factors were 
determined to play a substantial role in advanced AMD, while unique environments play a 
moderate role in development of AMD. Looking forward, these results highlight the need to find 
and investigate AMD-related genes. 
The methodologies used by Grizzard and Seddon differed in terms of sample size, 
participants, and AMD classification. In contrast to Grizzard’s study, the sample size of Seddon’s 
study was much larger, allowing for more stable analysis of subgroups. However, despite the 
large sample size, Seddon’s study was limited by its specific participant demographic. 
Participants only included male twin pairs born between 1917 and 1927 who served in the US 
armed forces, meaning that the results of this specific cohort may not be applicable to the general 
population. Furthermore, whereas Grizzard only included twin pairs in which at least one twin 
had AMD, Seddon did include twins without AMD. In fact, 39% of the total sample did not have 
AMD, allowing Seddon to calculate heritability estimates for AMD. In contrast to Grizzard’s 
study, in which any sign of AMD was generalized as a positive AMD diagnosis, Seddon’s study 
differentiated between the different stages of AMD. Based on a 5-stage grading system, AMD 
was classified as none (grade 1), early (grade 2), intermediate (grade 3), advanced dry (grade 4), 
or advanced neovascular (grade 5). Also distinct to this study was the inclusion of singletons in 
the analyses. The advantage to including singletons was that they could provide additional 
information about the association of traits within individuals. Despite differences in 
methodologies, both twin studies arrived at similar conclusions pointing to AMD as a heritable 
disease. 
 
 
Twin pair concordant 
for advanced AMD 
Twin pair 
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3.3 Conclusion 
 
Overall, the first-degree relative studies and twin studies reported here confirm that there 
is a large genetic contribution to AMD. The two first-degree relative studies showed that an 
individual who was related to someone with advanced AMD was more likely to also have AMD, 
than an individual who was not related to someone with advanced AMD. The two twin studies 
showed that MZ twins were more likely to have similar stages of AMD than DZ twins. Thus, 
genetics likely has a larger role in the etiology of AMD than environmental factors.  
 
 
Figure 13. Personalized nutrition: Establishing a genetic basis for the eye disease AMD. 
  
In the context of personalized nutrition, these heritability studies lay down a foundation 
establishing a strong genetic basis for AMD. Genes were shown to modulate occurrence of AMD, 
justifying further investigation into how genes may act as a link between dietary L/Z intake and 
AMD risk. Figure 13 highlights two points in the L/Z-AMD pathway at which genetic 
information can be used to create unique dietary recommendations that lead to the greatest 
reduced risk of AMD in individual patients. Moving forward, genotype and gene expression will 
be explored in relation to L/Z levels and AMD pathogenesis.
Nutrients 
Eye 
Disease 
Genotype 
Gene 
Expression    
Dietary L/Z Advanced AMD 
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Table 3. Clinical studies supporting a substantial genetic contribution to AMD.46-49 
First-Degree Relative Studies 
Reference Health Status Participants Analysis Results 
Seddon46 Advanced AMD 
in cases 
119 cases 
177 first-degree case relatives  
72 controls  
146 first-degree control relatives  
 
Compared prevalence of AMD in 
case relatives vs prevalence of 
AMD in control relatives  
Prevalence of AMD was significantly 
higher in relatives of cases than 
controls. Advanced AMD does have a 
familial component. 
Klaver47 Advanced AMD 
in cases 
87 cases  
186 first-degree case relatives 
135 controls  
343 first-degree control relatives  
 
Compared prevalence of AMD in 
case relatives vs prevalence of 
AMD in control relatives 
Prevalence of AMD was significantly 
higher in relatives of cases than 
controls. 23% of all advanced AMD 
was genetically determined. 
Twin Studies 
Reference Health Status Participants Analysis Results 
Grizzard48 Any AMD 25 twin pairs: 15 MZ + 10 DZ pairs  Compared concordance rates 
between MZ and DZ twin pairs 
Concordance of AMD was 
significantly higher in MZ twins than 
DZ twins. Genetics is important in the 
etiology of AMD. 
Seddon49 Advanced AMD 391 twin pairs: 210 MZ + 181 DZ pairs. 
Plus 58 singletons. 
Compared concordance rates 
between MZ and DZ twin pairs. 
Quantified relative contributions 
of genes and the environment on 
AMD. 
Concordance of advanced AMD was 
significantly higher in MZ twins than 
DZ twins. Genetic factors play a larger 
role in the etiology of AMD than 
environmental factors. 
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Chapter 4. Studies Evaluating How Genotype Affects Risk of Advanced AMD 
 
Genotype refers to the genetic makeup, or set of genes, in a person’s cells.23 These genes 
are largely responsible for an individual’s traits. Variations in genes between different persons 
correlate to differential responses to diet and subsequent differential development of disease 
states. This chapter will focus on how an individual’s genotype coordinates a unique response to 
diet. Currently, the literature as a whole has discovered many genes that are implicated in AMD. 
This review will only discuss genes related to L/Z transport to the retina.  
Given a specific set of genes related to L/Z metabolism, certain individuals may be 
predisposed to be at high risk of developing AMD. One factor that can increase an individual’s 
AMD risk is the impairment of L/Z transport in the body. After consuming fruits and vegetables 
in the diet, L/Z should be absorbed and transported to retinal cells, where they can accumulate in 
the macula and protect against AMD. HDL (high-density lipoprotein) may be involved in AMD 
pathogenesis due to its role as the major lipoprotein transporter of L and Z.24 Different variants in 
HDL-associated genes may change the efficiency by which L/Z undergo uptake and transport into 
the retina, thus modulating the risk of developing AMD.  
 
4.1 Overview of High-Density Lipoprotein (HDL) 
 
 HDL is composed of both protein and lipid.50 The protein fraction of HDL consists of 
apolipoproteins, while the lipid fraction includes phospholipids and cholesteryl esters. Out of all 
the lipoproteins in the body, HDL contains the highest proportion of protein. Structurally, HDLs 
are small spherical particles which have a polar outer shell and lipophilic inner core. 
A function of HDL is to transport lipophilic L/Z.24 After L/Z-containing foods have been 
digested, the fat-soluble L/Z must be coupled to a carrier in order to be transported in the aqueous 
blood. HDL is such a carrier, providing the lipophilic environment necessary for L/Z to be 
transported throughout the body. Once HDL-L/Z complexes reach the eye, HDL binds to 
apoliproprotein E (apoE) receptors in the retina. Binding of HDL to their target retinal receptors 
then releases L/Z into the retina.51 Therefore, variations in genes controlling HDL status may 
modulate the amount of L/Z that is transported into the retina. 
 
4.2 Variants in Genes Related to HDL Status 
 
4.2.1 Methodology 
 
Genetic variants that are important to a disease can be identified using a genome-wide 
association study (GWAS). Use of GWAS has increased significantly in the past decade as a 
result of large technological advancements in genotyping methods.52 In GWAS, a phenotype-to-
genotype approach is used to identify genetic variants that are significantly associated with 
human diseases. First, a very large population is phenotypically separated into cases and controls, 
based on whether they manifest the disease-of-interest. Then, all participants are genotyped to 
detect genetic variants, also known as SNPs (single nucleotide polymorphisms). Next, the 
frequency of genetic variants are compared between cases and controls. If there is greater 
frequency of a certain genetic variant in the case population (with disease) than the control 
population (without disease), then that variant is considered to be associated with the disease. 
 The main advantage to GWAS studies are that they are an unbiased, whole genome 
approach to identifying novel genes linked to common and complex diseases.52 The results of 
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GWAS are reliable, because there is a stringent threshold of statistical significance (typically P < 
5 × 10−8) for a genetic variant to be considered associated with the disease. However, there are 
some limitations to GWAS as well. Generally, GWAS may not accurately estimate the effect 
sizes and heritability explained by causal gene variants.53 The association signals detected from 
GWAS represent linkage between a common “tag” SNP and a causal SNP with a small effect 
size; thus, GWAS results may only explain a minor proportion of disease heritability. 
Additionally, common gene variants with subtle effects could be difficult to recognize as causal 
for the disease. 
This section will present four SNPs in three separate genes that were discovered by 
GWAS to be associated with AMD. Among all the AMD-associated genes implicated in GWAS 
studies, three genes were chosen for inclusion because they have important functions in the 
metabolism of HDL. Table 4 shows that a review of the LIPC, CETP, and ABCA1 genes will 
relate HDL status to AMD risk, pointing to HDL-mediated L/Z transport as one mechanism by 
which individuals are at differential risk of developing AMD. 
 
Table 4. Reported associations between variants in genes related to HDL status and risk of AMD.54-57  
Gene Function Locus 
Genotype 
Low AMD risk High AMD risk 
LIPC 
 
LIPC is involved in cellular 
uptake of HDL 
rs10468017 
rs493258 
TT 
TT 
CC 
CC 
CETP CETP is involved in the 
synthesis and degradation of 
HDL 
rs3764261 
 
CC AA 
 
ABCA1 
 
ABCA1 is involved in 
mediating the formation of 
HDL particles 
rs1883025 
 
TT CC 
 
 
4.2.2 Hepatic Lipase gene (LIPC) 
  
The hepatic lipase gene (LIPC) encodes hepatic triglyceride lipase (LIPC), which is an 
important enzyme in HDL metabolism that mediates HDL uptake at the cell surface.54 
Specifically, LIPC may function as a bridging factor for receptor-mediated HDL uptake. As 
depicted in Figure 14, LIPC that is expressed in the retina may promote the association of HDL 
with HDL-receptors on cell membranes, thus increasing the amount of L/Z that is delivered to 
retinal cells. Accordingly, genetic variants of LIPC may be implicated in AMD pathogenesis due 
to variation in the retinal uptake of L/Z by HDL.54 Here, GWAS studies have identified two 
genetic variants in the LIPC gene that are associated with advanced AMD, as shown in Table 4.  
 
26 
 
 
Figure 14. The role of LIPC in HDL-mediated L/Z uptake into retinal cells. In the macula of the 
eye, LIPC may function as a bridging factor for receptor-mediated HDL uptake. 
 
4.2.2.1 Locus rs493258 
 
The rs493258 locus, or position, near LIPC was found to be significantly associated with 
AMD in two GWAS studies.54,55 In 2010, Chen reported that a GWAS study had identified new 
genetic variants in LIPC that were associated with any AMD.55 A total of 7,749 cases and 4,625 
controls were genotyped. The results of this study found that the rs493258 locus in a promoter 
region near LIPC on chromosome 15 was strongly associated with AMD. Specifically, the C 
allele at rs493258 was observed to be associated with increased risk of AMD (OR = 1.14, 
overall P = 1.3 × 10−7). In this study, even though the association signal for a variant at LIPC 
rs493258 was strong, the association was not statistically significant. However, LIPC rs493258’s 
association with AMD was found to be significant in a companion GWAS study.54 
In the companion 2010 GWAS study, Neale similarly identified new genetic variants in 
LIPC that were associated with AMD.54 However, Neale’s study differed from the previous study 
by only including cases with advanced AMD. Thus, a slightly smaller sample size of 5,789 cases 
and 4,234 controls were genotyped. The results of this study found the rs493258 locus near LIPC 
to be significantly associated with advanced AMD (P = 1.61 × 10−8).  
A 2013 GWAS study by Lee aimed to replicate Neale’s GWAS finding of a significant 
association between LIPC and advanced AMD.56 As a smaller GWAS study with 3,785 cases of 
advanced AMD and 2,009 controls, Lee specifically focused on confirming the associations 
between previously-reported LIPC variants and advanced AMD. The results were indeed 
consistent with Neale’s large GWAS, in which the LIPC variant rs493258 was significantly 
associated with advanced AMD (P = 1.21× 10−4). 
The association of LIPC risk loci and advanced AMD was further confirmed by Cipriani 
in a 2012 GWAS study of participants living in the UK.57 Using a small discovery cohort of 893 
cases and 2199 controls, Cipriani’s study aimed to confirm LIPC rs493258 as a probable AMD 
susceptibility locus. Indeed, their results showed that the LIPC variant rs493258 was weakly 
associated with advanced AMD (P = 0.04). Specifically, the T allele at rs493258 had a weak 
protective effect against advanced AMD (OR = 0.89). Taken together with Chen’s results, the C 
allele at rs493258 was associated with increased risk of AMD, and the T allele was associated 
with decreased risk of advanced AMD. 
LIPC 
L+Z 
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4.2.2.2 Locus rs10468017 
 
Another genetic variant in the promoter region of LIPC, the rs10468017 locus, was found 
to be significantly associated with advanced AMD in two GWAS studies.54,56 In Neale’s 2010 
GWAS study, the LIPC variant that was most strongly associated with advanced AMD was the 
functional promoter variant, rs10468017 (P = 1.34× 10−8).54 In Lee’s smaller-sized GWAS study, 
rs10468017 was confirmed to be significantly associated with advanced AMD (P = 1.67× 10−3).56 
Specifically, the minor allele, T, was associated with a reduced risk of AMD (OR = 
0.82).54 When the neovascular form of advanced AMD was analyzed separately, the T allele had 
a similar protective effect (OR = 0.77).  
In contrast, LIPC rs10468017 was not found to be associated with advanced AMD in 
Cipriani’s small GWAS study of UK participants.57 Using a small discovery cohort of 893 cases 
and 2199 controls, the T allele of LIPC rs10468017 was not associated with reduced risk of 
advanced AMD (P = 0.11, OR = 0.91). However, this study was limited by its small sample size. 
The discovery GWAS did not have the statistical power necessary to detect weak associations, 
such as that between LIPC rs10468017 and advanced AMD. 
 
4.2.2.3 LIPC, HDL Levels, and AMD Pathogenesis 
 
Overall, LIPC variants at rs493258 and rs10468017 may confer differential risk of 
developing advanced AMD. As shown in Table 4, individuals with TT alleles at rs493258 or 
rs10468017 were less likely to have advanced AMD. On the other hand, individuals with CC 
alleles at rs493258 or rs10468017 were more likely to have advanced AMD.  
Regarding the contribution of LIPC to AMD pathogenesis, HDL-associated genetic 
variants may modulate the amount of L/Z that is delivered into the retina. In essence, how do 
serum levels of HDL affect the risk of developing AMD, if at all? Given that the T allele is 
known to increase HDL levels,58 the relationship between LIPC-modulated HDL levels and 
advanced AMD could be characterized. Namely, an HDL-raising allele of LIPC was suggested to 
decrease risk of advanced AMD. The implications of this effect will be discussed in the 
conclusions section. 
 
4.2.3 Cholesteryl Ester Transfer Protein gene (CETP) 
 
The cholesteryl ester transfer protein gene (CETP) encodes cholesteryl ester transfer 
protein (CETP), which is involved in the transfer of cholesteryl ester and triglycerides between 
HDL and another lipoprotein, VLDL (Very Low-Density Lipoprotein).54 Thus, CETP plays an 
important role in the synthesis and degradation of HDL. 
Figure 15 shows how CETP impacts HDL and L/Z status. CETP transfers cholesteryl 
esters from HDL to VLDL (a), and transfers triglycerides from VLDL to HDL (b). Thus, CETP 
can decrease or increase levels of plasma HDL, respectively. If there are decreased levels of 
HDL, less L/Z is able to be transported by HDL to the retina (c). With less HDL available to bind 
to HDL-receptors (d), there is decreased delivery of L/Z into retinal cells (e). On the other hand, 
if there are increased levels of HDL, more L/Z is able to be transported by HDL to the retina (f). 
With more HDL available to bind to cell membrane HDL-receptors (g), there is increased 
delivery of L/Z into retinal cells (h).  
Given its role in HDL synthesis and degradation, CETP may modulate the amount of 
HDL that are available to deliver L/Z into retinal cells. Accordingly, genetic variants of CETP 
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may be implicated in AMD pathogenesis due to variation in the uptake and transport of L/Z by 
HDL.54 Here, GWAS studies have identified one genetic variant in the CETP gene that is 
associated with AMD, as shown in Table 4. 
 
 
 
Figure 15. The role of CETP in HDL metabolism and L/Z transport in retinal cells. CETP is 
involved in the synthesis and degradation of plasma HDL. Thus, CETP may modulate the amount 
of HDL-carrying L/Z that reach the retina. 
 
4.2.3.1 Locus rs3764261 
 
The rs3764261 promoter locus near CETP was found to be significantly associated with 
AMD in two GWAS studies.54,55 In 2010, Chen’s large GWAS study that genotyped 7,749 cases 
and 4,625 controls identified new associations between CETP variants and any AMD.55 The 
results of Chen’s study found that the A allele at rs3764261 on chromosome 16 was found to be 
associated with increased risk of AMD (OR = 1.19, overall P = 7.4 × 10−7). It should be noted 
that even though the association signal near CETP was strong, it did not reach genome-wide 
significance in Chen’s study. Nonetheless, the CETP signal likely reflected a real association with 
AMD, since less than 0.3 loci per scan were expected to reach P < 3 × 10−7 by chance.  
Similar results were reported in a companion 2010 GWAS study.54 In Neale’s slightly 
smaller GWAS of 5,789 cases and 4,234 controls, the CETP variant at rs3764261 was found to be 
related to the advanced stage of AMD. Consistent with Chen’s result, the A allele was found to be 
weakly associated with increased risk of AMD (P = 1.41× 10−7).  
In contrast, CETP rs3764261 was not found to be associated with advanced AMD in 
Cipriani’s small GWAS study of UK participants.57 Using a small discovery cohort of 893 cases 
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and 2199 controls, this small GWAS did not appear to support the previously reported CETP 
rs3764261 as a probable AMD susceptibility locus. However, Cipriani’s study was limited by its 
small sample size. The discovery GWAS did not have the statistical power necessary to detect 
weak associations, such as that between CETP rs3764261 and advanced AMD.  
 
4.2.3.2 CETP, HDL Levels, and AMD Pathogenesis 
 
Overall, CETP variants at rs3764261 may confer differential risk of developing AMD. As 
shown in Table 4, individuals with AA alleles at rs3764261 were more likely to have AMD. On 
the other hand, individuals with CC alleles at rs3764261 were less likely to have AMD. 
Regarding the relationship between CETP and AMD pathogenesis, how do serum levels 
of HDL affect the risk of developing AMD, if at all? Given that the A allele is known to increase 
HDL levels,59 the relationship between CETP-modulated HDL levels and advanced AMD could 
be characterized. Namely, an HDL-raising allele of CETP was suggested to increase risk of 
advanced AMD. Interestingly, this increased risk is opposite of the protective effect observed 
with the HDL-raising LIPC allele. Although both CETP and LIPC alleles raise HDL levels in the 
blood, they may have opposing effects on AMD risk. The implications of these effects will be 
discussed in the conclusions section. 
 
4.2.4 ATP-Binding Cassette Protein gene (ABCA1) 
 
The ATP binding cassette subfamily A member 1 gene (ABCA1) encodes for an ATP-
binding cassette protein (ABCA1), which moves cholesterol across cell membranes to the outside 
of the cell.60 Thus, ABCA1 functions as a cholesterol efflux pump.   
Figure 16 shows how ABCA1 impacts HDL and L/Z status. In the body and eyes, 
ABCA1 is involved in efflux of cholesterol from somatic cells (a) and retinal cells (b). Once 
outside the cell, free cholesterol is transported in the bloodstream to the liver (c). In the liver, 
cholesterol then combines with other fats and proteins to form HDL (d). These HDL can then 
pick up L/Z in the bloodstream (e), and carry these dietary carotenoids to the retina (f). In the 
retina, HDL can bind to HDL-receptors (g) and deliver L/Z into retinal cells (h).  
Given its role in cholesterol efflux, ABCA1 may modulate the amount of HDL that are 
synthesized and available to deliver L/Z into retinal cells. Accordingly, genetic variants of 
ABCA1 may be implicated in AMD pathogenesis due to variation in the uptake and transport of 
L/Z by HDL.54 Here, GWAS studies have identified one genetic variant in the ABCA1 gene that is 
associated with AMD, as shown in Table 4. 
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Figure 16. The role of ABCA1 in HDL metabolism and L/Z transport in retinal cells. ABCA1 
may modulate the amount of HDL that is synthesized, thus regulating how much HDL is available 
to deliver L/Z into retinal cells. 
 
4.2.4.1 Locus rs1883025 
 
The rs1883025 locus in an intronic region of ABCA1 was found to be significantly 
associated with AMD in two GWAS studies.54,55 In 2010, Chen’s large GWAS study that 
genotyped 7,749 cases and 4,625 controls identified new associations between ABCA1 variants 
and any AMD.55 Generally, HDL-associated alleles near ABCA1 showed weak associations with 
AMD (P = 5.6 × 10−4). Specifically, the C allele at rs1883025 was associated with increased risk 
of AMD (OR = 1.15).  
Similar results were reported in a companion 2010 GWAS study. In Neale’s slightly 
smaller GWAS of 5,789 cases and 4,234 controls, the potential association between rs1883925 
and the advanced stage of AMD was confirmed.54 Consistent with Chen’s result, the ABCA1 
variant at rs1883025 was weakly associated with advanced AMD (P = 9.73 × 10−4).  
 
4.2.4.2 ABCA1, HDL Levels, and AMD Pathogenesis 
 
Overall, ABCA1 variants at rs1883025 may confer differential risk of developing AMD. 
As shown in Table 4, individuals with CC alleles at rs3764261 were more likely to have AMD. 
On the other hand, individuals with TT alleles at rs3764261 were less likely to have AMD. 
Regarding the relationship between ABCA1 and AMD pathogenesis, how do serum levels 
of HDL affect the risk of developing AMD, if at all? Since the C allele is known to increase HDL 
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levels,61 the relationship between ABCA1-modulated HDL levels and advanced AMD could be 
characterized. Namely, an HDL-raising allele of ABCA1 was suggested to increase risk of 
advanced AMD. Interestingly, this increased risk is opposite of the protective effect observed 
with the HDL-raising LIPC allele, but consistent with the risk-increasing effect of the HDL-
raising LIPC allele. The implication of these observed inconsistencies will be discussed in the 
conclusions section. 
 
4.3 Evaluation of GWAS Results 
 
It should be noted that these studies have limitations that may affect the interpretation of 
overall results. Notably, only Caucasian participants were included in these GWAS studies. It is 
possible that populations of different ethnicities may affect the observed associations between 
genetic variants and AMD. Furthermore, the range of sampled geographical locations was 
restricted, with three GWAS studies conducted in the US, and only one conducted in the UK. 
Therefore, the reported findings may not be generalized. It is necessary to investigate associations 
in different ethnic populations from various regions of the world. Consideration should also be 
given to the fact that most of these GWAS studies implicated many other genes, in addition to 
LIPC, CETP, and ABCA1, that are involved in various other processes in the body. Thus, the 
effects of these three HDL-related genes on L/Z status, and consequently AMD development, 
may not be very large. 
 
4.4 Conclusion 
 
Overall, GWAS studies have identified genetic variants, at rs493258 and rs10468017 
(LIPC), rs3764261 (CETP), and rs1883025 (ABCA1), that are involved in HDL metabolism and 
may be associated with advanced AMD. So far, these SNPs have not been strongly associated 
with other diseases. It has been suggested that these genetic variants may contribute to coronary 
artery disease, which is plausible given their roles in lipid metabolism.58,59,61 However, these 
associations still need to be clarified. 
On the other hand, more research has focused on the association between these HDL-
related SNPs and AMD. Because L and Z are preferentially carried on HDLs, blood HDL 
distribution may be an important indicator of L/Z accumulation in the retina and, subsequently, 
AMD risk.24 However, Table 5 shows that there does not appear to be a straightforward 
correlation between HDL levels and AMD. The HDL-raising T allele of LIPC was suggested to 
decrease risk for AMD. In contrast, the HDL-raising A allele of CETP and HDL-raising C allele 
of ABCA1 may increase risk for AMD, although these associations are currently not genome-wide 
significant. Altogether, three alleles that increase HDL levels were observed to impact AMD risk 
in opposite directions. The observed contradictory associations between serum HDL and 
advanced AMD suggest that HDL levels do not have a causal effect on advanced AMD.54 Instead, 
there must be alternative biologic mechanisms by which HDL-associated gene variants affect 
susceptibility of AMD.  
 
Table 5. Reported relationships between risk of AMD and the HDL-raising alleles of three genes involved 
in HDL metabolism.58,59,61  
 LIPC CETP ABCA1 
HDL-raising allele Decreased AMD risk Increased AMD risk Increased AMD risk 
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One alternative biologic mechanism involves changes in HDL-related efficiency of L/Z 
delivery. For example, variants in the rs493258 or rs10468017 promoter region of LIPC influence 
the amount of LIPC that is transcribed and available to be translated into active enzymes. The 
concentration of LIPC enzymes in the retina may consequently determine the efficiency by which 
HDL particles bind to HDL-receptors. The more LIPC there is in the retina, the more likely it is 
that HDL will associate with its receptor, delivering more L/Z into retinal cells. For CETP and 
ABCA1, current understanding of their effects on HDL metabolism is limited to their effects on 
serum HDL levels. Alternative mechanisms by which CETP and ABCA1 impact HDL-associated 
L/Z delivery into the retina should be explored.  
In the context of personalized nutrition, the discovery of AMD-susceptibility alleles 
highlights the advantage to using genomic information to form nutritional recommendations that 
effectively decrease risk of advanced AMD. Based on HDL’s suggested role as the major 
lipoprotein transporter of L/Z,24 genetic variants associated with HDL status may affect how 
much L/Z is transported into the retina. Figure 17 depicts how genotyping fits into the concept of 
personalized nutrition. The genetic information extracted from genotyping for HDL-related 
genetic variants is important for pinpointing individuals at high-risk for AMD. Such high-risk 
individuals may require higher dietary intakes of L/Z.  
 
 
Figure 17. Personalized nutrition: Genotyping for genetic variants in HDL-related genes. 
Individuals with certain alleles in HDL-related genes are at higher risk for AMD and require 
higher intakes of L/Z.  
 
This section reviewed four genetic variants that may be involved in HDL-related L/Z 
transport. After L/Z has been transported by HDL to the retina and taken up by retinal cells, they 
may then regulate the transcription of genes. The next section will investigate the effect of L on 
inflammatory gene expression, pointing to a genetic mechanism by which L is protective against 
the development of AMD. 
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Chapter 5. Studies Evaluating How L Alters Expression of Genes Involved in AMD 
Pathogenesis 
 
Between the dietary macular pigments L and Z, L is found at greater concentration in a 
wider variety of fruits and vegetables. Correspondingly, most published studies elucidating the 
mechanism by which dietary macular pigments affect AMD have focused solely on the effects of 
L. Currently, L is widely recognized as protecting eye tissue against photooxidative damage via 
two mechanisms: first as a filter for harmful high-energy light and second as an antioxidant that 
quenches ROS.12 Additionally, a chronic inflammatory response may be involved in AMD 
pathogenesis.25 However, the role of L in ocular inflammation has been much less-studied. In this 
section, three studies will be presented to understand the genetic mechanism by which L is anti-
inflammatory against development of AMD. Table 6 compares the methodologies of three 
studies, all of which used the in vitro system of RAW264.7 macrophages to investigate the effect 
of L on an inflammatory response potentially involved in AMD pathogenesis. All studies 
stimulated inflammatory conditions in a model cell, and compared levels of target molecules 
before and after L incubation. 
 
Table 6. Studies using the in vitro system of RAW264.7 macrophages to investigate the effect of lutein on 
an inflammatory response potentially involved in AMD pathogenesis. Comparison of inflammatory 
molecule expression in conditions of inflammation with and without L reveal the mechanism by which L is 
anti-inflammatory. 
Study System Inflammation 
Stimulation 
Lutein Target Inflammatory 
Molecules 
Jin62 RAW264.7 cells 1000 ng/mL LPS 18 μM  iNOS, COX-2, IκB  
 
Izumi-Nagai63 RAW264.7 cells 100 ng/mL LPS 18 μM  VEGF 
 
Kim64 RAW264.7 cells 100 ng/mL LPS 
200 μM H2O2 
20 μM  iNOS, COX-2, IκB, NO, 
PGE2, NF-κB, H2O2, IKK, 
Akt, NIK, PTEN, and PI3K 
 
5.1 Inflammatory Response 
 
5.1.1 Methods in vitro: RAW264.7 cells 
 
All three studies used the in vitro system of RAW264.7 cells to study the anti-
inflammatory effects of L. As a mouse macrophage cell line, RAW264.7 was the chosen model 
system because these cells are very sensitive to stimulation by the endotoxin LPS 
(lipopolysaccharide), and they respond by activating proinflammatory targets.65 Thus, 
inflammatory conditions that may be involved in AMD pathogenesis were simulated in 
RAW264.7 cells by incubation with LPS. It should be noted that although RAW264.7 cells are 
not the types of macrophages found in an eye with AMD, they are a useful model because they 
can be easily manipulated to mimic the inflammatory conditions of AMD. Similarly, although 
LPS is not known to directly cause AMD, LPS was used as a model for a type of inflammation 
leading to AMD because RAW264.7 cells are easily stimulated by LPS. 
Theoretically, LPS-stimulation should increase the expression of proinflammatory genes, 
while the addition of L should suppress the LPS-stimulated increase in expression of 
proinflammatory genes. Thus, the levels of genes and molecules in RAW264.7 cells were 
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analyzed in three conditions: no stimulation, LPS-stimulation, and LPS-stimulation plus L. 
Comparison between these three conditions revealed the inflammation-associated signaling 
pathway that is targeted by L in the cell. 
The methodology used to prepare RAW264.7 cells was similar in all three studies. First, 
RAW264.7 cells were pretreated with various concentrations of L, ranging from 1 μg/mL to 100 
μg/mL. Next, RAW264.7 cells were stimulated with LPS. One study used 1000 ng/mL LPS62, 
while the other two studies used 100 ng/mL LPS.63,64 Lysates and/or total RNA were then 
extracted from RAW264.7 cells and analyzed. 
 
5.1.2 Methods in vitro: The Inflammatory Nuclear Factor NF-κB Pathway 
 
The nuclear factor NF-kB pathway is widely accepted as a typical proinflammatory 
signaling pathway.66 As a protein complex, NF-kB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) generally functions as a regulator of DNA transcription. NF-kB itself is a 
central molecule in the inflammatory response, acting as a link between upstream 
proinflammatory cytokines and downstream transcription of proinflammatory genes. Generally, 
the NF-kB pathway is activated upon cellular stimulation, such as LPS-induced oxidative stress. 
Stimulation initiates a signaling cascade of proinflammatory cytokines, leading to the activation 
of NF-kB. Activated NF-κB dimers are released from a cytoplasmic NF-κB–IκB complex and 
freed to translocate to the nucleus.67 Once inside the nucleus, NF-κB binds to enhancer and 
promoter elements of proinflammatory genes. Ultimately, NF-κB induces the transcription of 
proinflammatory cytokines, chemokines, and adhesion molecules.  
The proinflammatory targets investigated by these three studies were all involved in the 
NF-κB signaling pathway. Western blot analysis or ELISA (enzyme-linked immunosorbent 
assay) was performed to measure relative protein levels. RT-PCR (reverse transcription 
polymerase chain reaction) was performed to measure mRNA levels. EMSA (electrophoretic gel 
mobility shift assay) was performed to measure binding activity between transcription factors and 
DNA. ChIP (chromatin immunoprecipitation assay) was performed to determine what DNA 
regions a transcription factor binds to.  
Measurements were obtained for upstream mediators of the NF-κB pathway, proteins 
directly participating in NF-κB activation, and genes transcribed by NF-κB activation. Table 7 
describes the proteins and genes analyzed across the three studies. Upstream mediators of the NF-
κB pathway include H2O2 (hydrogen peroxide), PI3K (phosphoinositide 3-kinase), PTEN 
(phosphatase and tensin homolog), IKK (inhibitor of nuclear factor kappa-B kinase), Akt (protein 
kinase B), and NIK (nuclear factor-kappa-B-inducing kinase). Proteins directly participating in 
NF-κB activation include NF-κB (nuclear factor kappa B) and IκB (inhibitor kappa B). Genes 
transcribed by NF-κB activation include iNOS (inducible nitric oxide synthase), COX-2 
(cyclooxygenase), and VEGF (vascular endothelial growth factor). Metabolites downstream of 
NF-κB-activated genes were also measured, including NO (nitric oxide) and PGE2 (prostaglandin 
E2). 
Frequently, the protein levels of these genes were analyzed instead of mRNA levels. 
Analyzing protein expression over RNA expression is advantageous because protein levels reflect 
the subset of active RNA. Often, RNA can be silenced or degraded before being translated into 
proteins. Thus, protein analysis reveals the proportion of RNA that actually leads to inflammatory 
effects in the cell. 
 
 
35 
 
Table 7. Proteins and genes involved in the inflammatory NF-κB pathway. 
Section of NF-κB 
Pathway 
Target Form Function 
Genes transcribed by 
NF-κB activation 
iNOS - Proinflammatory gene/protein 
COX-2 - Proinflammatory gene/protein 
VEGF - Proinflammatory protein 
Proteins directly 
participating in NF-κB 
activation 
IκB Unphsophorylated Binds to and sequesters NF-κB in 
cytoplasm 
 Phosphorylated Tagged for degradation; no longer 
binds to NF-κB in cytoplasm 
NF-κB Cytosolic Inactive transcription factor 
 Nuclear Active transcription factor that 
binds to promoter region of DNA 
Upstream mediators of 
the NF-κB pathway 
PTEN Reduced Indirectly inactivates Akt 
 Oxidized Does not inhibit Akt 
PI3K - Indirectly activates Akt 
Akt Phosphorylated Phosphorylated (active) Akt 
phosphorylates IKK 
NIK Phosphorylated Phosphorylated (active) NIK 
phosphorylates IKK 
IKK Phosphorylated Phosphorylated (active) IKK 
phosphorylates IκB 
 
5.1.3 Results in vitro 
 
The first study to investigate L’s effect on ocular inflammation in AMD pathogenesis 
was reported in 2006.62 Using the in vitro system of RAW264.7 cells, Jin aimed to understand the 
molecular mechanism by which L treatment affected LPS-induced RAW264.7 cells.62  
The overall results showed that L had an anti-inflammatory effect in vitro. Before LPS-
stimulation, RAW264.7 cells had no expression of iNOS or COX-2 proteins. After LPS-
stimulation, expression of iNOS and COX-2 proteins increased dramatically (1.5 signal intensity 
and 1.1 signal intensity, respectively). Notably, LPS-stimulated cells that were pretreated with L 
had lower expression of both iNOS and COX-2 proteins. Thus, L inhibited LPS-induced 
increases in the proinflammatory iNOS and COX-2 protein levels. 
To elucidate the mechanism underlying L’s effect, the protein levels of IκB were 
examined. Before LPS-stimulation, RAW264.7 cells had a large amount of IκB in the cytoplasm 
(0.8 signal intensity). After LPS-stimulation, the amount of cytosolic IκB decreased significantly 
(0.2 signal intensity). Notably, LPS-stimulated cells that were pretreated with L had increased 
levels of cytosolic IκB. Thus, L likely inhibited the LPS-induced degradation of IκB in the 
cytoplasm.  
Jin’s results were supported by a separate study one year later. In 2007, Izumi-Nagai also 
used the in vitro system of RAW264.7 cells to examine how L altered expression of a 
proinflammatory molecule.63 In contrast to the previous study, this study investigated the change 
in expression of an inflammatory protein, VEGF, specifically involved in development of 
choroidal neovascularization (CNV). CNV occurs when new blood vessels form in the choroid 
layer of the eye, which is the main criteria for diagnosing the neovascular form of advanced 
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AMD. Thus, this study refined L’s anti-inflammatory mechanism to include regulation of VEGF, 
which specifically promotes the development of advanced neovascular AMD.  
The overall result showed that L had an anti-inflammatory effect in vitro. Before LPS-
stimulation, RAW264.7 cells had a low amount of VEGF protein (approximately 50 pg/mg). 
After LPS-stimulation, there was a significantly increased amount of VEGF (approximately 110 
pg/mg). Notably, LPS-stimulated cells that were pretreated with L had reduced levels of VEGF 
(70-80 pg/mg). Thus, L inhibited the LPS-induced increase in VEGF.  
From the previous two studies, L appeared to exert its anti-inflammatory effect by 
inhibiting the production of proinflammatory proteins such as iNOS, COX-2, and VEGF. Figure 
18 depicts one possible mechanism by which L is anti-inflammatory in RAW264.7 cells. In 
untreated inflammatory conditions, cytosolic IκB is degraded. Degradation of IκB frees NF-κB, 
which is normally bound to IκB in the cytoplasm, to translocate into the nucleus. NF-κB binds to 
DNA and up-regulates the expression of proinflammatory genes encoding iNOS, COX-2, and 
VEGF. However, Figure 18 depicts L-treated inflammatory conditions, in which L suppressed 
degradation of cytosolic IκB. If cytosolic IκB is not degraded, NF-κB cannot be activated 
(translocate from the cytoplasm into the nucleus). Consequently, there is decreased transcription 
of inflammation-related genes, and ultimately a decreased amount of inflammatory proteins in the 
cell.  
 
Figure 18. The results of Jin62 and Izumi-Nagai63 showing lutein’s anti-inflammatory effect. 
Incubating LPS-stimulated RAW264.7 cells with lutein inhibits the expression of proinflammatory 
proteins, likely by suppressing the degradation of cytosolic IκB.  
 
One year later, a comprehensive study further expanded this suggested mechanism for 
L’s anti-inflammatory effect. In 2008, Kim used the in vitro system of RAW264.7 macrophages 
to elucidate alternative mechanisms by which L may modulate immune responses.64 Improving 
on the previous two studies, this study provided a comprehensive investigation into the 
downstream targets of NF-κB pathway, NF-κB activation itself, and upstream modulators of NF-
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κB pathway. In doing so, other targets through which L could regulate transcription of 
inflammation-related genes were discovered.  
The overall results showed that L had an anti-inflammatory effect in vitro. L was 
observed to inhibit cellular targets that will be generalized into three groups: 1) inflammation-
related genes and proteins, 2) NF-κB signaling, and 3) H2O2-stimulated signaling.   
First, Figure 19 shows that L suppressed the expression of inﬂammation-related genes 
and corresponding proteins. Consistent with the results of Jin’s 2006 study, L inhibited both the 
iNOS-NO pathway and the COX2-PGE2 pathway. Before LPS-stimulation, RAW364.7 cells had 
very low levels of iNOS mRNA, iNOS protein, NO (1 μM), COX-2 mRNA, COX-2 protein, and 
PGE2 (1 ng/ml). After LPS-stimulation, RAW364.7 cells had increased levels of iNOS mRNA, 
iNOS protein, NO (20 μM), COX-2 mRNA, COX-2 protein, and PGE2 (6 ng/ml). LPS-
stimulated cells that were pretreated with 20 μM L inhibited the changes seen with LPS-
stimulation: L decreased levels of iNOS mRNA, iNOS protein, NO (4 μM), COX-2 mRNA, 
COX-2 protein, and PGE2 (3 μM). Thus, L was confirmed to decrease the production of pro-
inflammatory molecules. 
               A 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
             B 
 
 
 
Figure 19. Adapted from Izumi-Nagai and Kim.63,64 Lutein inhibits LPS-induced NF-κB signaling 
and downstream expression of inflammatory proteins. RAW264.7 cells were treated with LPS 
(100 ng/ml) in the presence of lutein (20 μM). (A) Observed protein levels of inflammatory and 
NF-κB molecules. (B) Observed mRNA levels of iNOS and COX-2. 
 
Secondly, Figure 19A shows that L inhibited NF-κB signaling by decreasing both NF-κB 
activation and NF-κB promoter activity. To refine the results of Jin’s 2006 study, which only 
analyzed levels of cytosolic IκB, this study analyzed the levels and activity of NF-κB. These 
measurements confirmed the NF-κB pathway as a target for L in down-regulating inflammatory 
genes. Before LPS-stimulation, NF-κB were predominantly expressed in the cytosol, and there 
was almost no binding between NF-κB and the iNOS promoter. After LPS-stimulation, NF-κB 
were predominantly expressed in the nucleus, and there was significantly increased binding 
between NF-κB and the iNOS promoter. LPS-stimulated cells that were pretreated with 20 μM L 
inhibited the changes seen with LPS-stimulation: L increased cytosolic NF-κB and decreased 
nuclear NF-κB, as well as decreased binding between NF-κB and the iNOS promoter. Thus, L 
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decreased production of a proinflammatory protein by inhibiting the translocation of NF-κB into 
the nucleus, such that less NF-κB was available to bind to the promoter of an inflammatory gene. 
Thirdly, Figure 20 shows that L suppressed H2O2 accumulation and inhibited H2O2-
induced NF-κB activation signals. Briefly, the upstream H2O2 pathway involves a cascade of 
proteins. When a signaling protein is phosphorylated, it becomes active. The active protein then 
phosphorylates (activates) another protein, and so on. Antibodies can be used to selectively 
recognize the phosphorylated (active) form of a protein. 
The results showed that before H2O2-stimulation, RAW264.7 cells had almost no 
intracellular H2O2 (less than 1% relative intensity), and had low levels of p-IκB (phosphorylated-
IκB), p-IKKαβ, p-Akt, p-NIK, oxidized PTEN, and PI3K activity. After H2O2-stimulation, 
RAW364.7 cells had dramatically increased H2O2 (100% relative intensity), and had increased 
levels of p-IκB, p-IKKαβ, p-Akt, p-NIK, oxidized PTEN, and PI3K activity. H2O2-stimulated 
cells that were pretreated with 20 μM L inhibited the changes seen with H2O2-stimulation: L 
decreased H2O2 accumulation (13% relative intensity), and decreased levels of p-IκB, p-IKKαβ, 
p-Akt, p-NIK, oxidized PTEN, and PI3K activity. Thus, L decreased expression of inflammatory 
genes by suppressing intracellular levels of H2O2, which subsequently inhibited the 
PI3K/PTEN/Akt and NIK/IKK pathways upstream of the NF-κB pathway.  
 
 
 
 
 
 
  
Figure 20. Adapted from Kim.64 Lutein inhibits H2O2-induced NF-κB activation mediators. 
RAW264.7 cells were treated with H2O2 (200 μM) in the presence of lutein (20 μM). After 10 
minutes, the levels of signaling proteins were measured. (Top) Observed protein levels of PTEN 
and PI3K using immunoblot analysis. (Bottom) Observed protein levels of phosphorylated Akt, 
NIK, and IKK using western blot analysis.  
 
 Generally, this study analyzed a widespread set of genes and proteins to get a 
comprehensive understanding of the mechanism underlying L’s anti-inflammatory effect. When 
these results are combined with the findings of the previous two studies, a signaling pathway can 
be assembled to elucidate how L down-regulates the expression of inflammatory genes and 
proteins.  
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5.1.4 Proposed Mechanism of L’s Anti-Inflammatory Effect 
 
In AMD pathogenesis, upregulation of the inflammatory pathway may contribute to the 
degeneration of the macula. Figure 21 proposes an inflammatory pathway that is targeted by L 
treatment in LPS-stimulated RAW264.7 cells. Upon stimulation with LPS, extracellular H2O2 is 
generated. The extracellular H2O2 then crosses into the cell, leading to the accumulation of 
intracellular H2O2. H2O2 inside the cell then activates PI3K and NIK, which subsequently 
phosphorylate and activate their corresponding cytokines. Both PI3K and NIK signaling 
pathways converge on the phosphorylated activation of IKK, which then phosphorylates IκB. 
Phosphorylated IκB is tagged for degradation, allowing NF-κB to dissociate from IκB and 
translocate into the nucleus. Once inside the nucleus, NF-κB binds to the promoter region of 
inflammatory genes, which increases their transcription. These inflammatory genes are then 
translated into proteins, which can go on to promote inflammation in tissues such as those 
comprising the macula of the eye.  
 
 
Figure 21. Adapted from Kim.64 Lutein inhibits the inflammation-related NF-κB pathway. H2O2 
and IκB may be potential therapeutic targets for L’s suppression of NF-κB-regulated inﬂammatory 
gene expression. Both extracellularly and intracellularly, L scavenges H2O2. Additionally, L 
inhibits degradation of IκB in the cytosol.  
 
Figure 21 pinpoints H2O2 and IκB as potential therapeutic targets for L’s suppression of 
NF-κB-regulated inﬂammatory gene expression. Lutein scavenges both extracellular and 
intracellular H2O2, such that less H2O2 accumulates in the intracellular space. Less intracellular 
H2O2 corresponds to reduced levels of active NIK and PI3K, and increased levels of active PTEN. 
Thus, the PI3K/PTEN/Akt and NIK/IKK pathways are inhibited with L treatment. Both pathways 
converge on inactive IKK, which does not phosphorylate IκB. Unphosphorylated IκB is not 
degraded and remains bound to NF-κB in the cytoplasm. NF-κB is thus sequestered in the 
cytoplasm and unable to translocate into the nucleus. Without NF-κB binding to the promoters of 
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DNA, there is very low transcription of inflammatory genes. Consequently, there is less 
production of proinflammatory proteins such as iNOS, COX-2, and VEGF. Overall, incubating 
LPS-stimulated RAW264.7 cells with L was observed to decrease the expression of 
proinflammatory molecules that arise from NF-κB signaling. 
 
5.2 Conclusion 
 
Overall, L’s anti-inflammatory effect was suggested to result from the transcriptional 
down-regulation of inflammatory molecules. The transcription of inflammatory genes was 
directly mediated by the NF-κB pathway, and indirectly mediated by the H2O2-dependent 
PI3K/Akt pathway and H2O2-dependent NIK pathway. The studies presented here found that L 
may have an anti-inflammatory effect on intraocular inflammation, by inhibiting the NF-κB 
dependent signaling pathway upstream of the production of proinflammatory molecules. 
In vivo, the amount of L that is available to down-regulate inflammatory molecules may 
be dependent on HDL status. Genetic variants in HDL-related genes were previously proposed to 
modulate the efficiency by which L/Z undergo uptake and transport into the retina. Increased 
HDL-mediated transport of L leads to a greater concentration of L inside retinal cells. There, L 
scavenges H2O2 and inhibits IκB degradation, decreasing inflammation of retinal cells. 
Suppressing inflammation in the retinal pigment epithelium potentially delays the development of 
advanced AMD. The overall HDL-inflammation pathway is potentially one mechanism by which 
L reduces risk of advanced AMD.  
In the context of personalized nutrition, genetic information that reveals differential 
expression of inflammatory genes can be used to create personalized nutritional recommendations 
that most effectively delay advanced AMD. Figure 22 depicts how genetic information 
concerning gene expression fits into the concept of personalized nutrition. Individuals who are 
more susceptible to chronic inflammatory responses involving the iNOS, COX-2, and VEGF 
genes may require higher levels of L. Concerning the overall HDL-inflammation pathway, 
patients with certain LIPC, CETP, and ABCA1 alleles, as well as chronic expression of NF-κB 
dependent inflammatory genes, should likely consume the highest amounts of L/Z.  
 
Figure 22. Personalized nutrition: Profiling the expression of NF-κB dependent proinflammatory 
genes. Individuals who are more susceptible to chronic expression of inflammatory genes are at 
higher risk for AMD and require higher intakes of L.  
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Chapter 6. Future Directions 
 
 Current research in the nutrigenomics of AMD has largely focused on epidemiological 
studies analyzing the association between L/Z intake and AMD risk. The literature as a whole 
consists of a large amount of cross-sectional studies, prospective studies, and randomized clinical 
trials, all of which report associations between L/Z in the diet, serum, or supplements, and any 
type of AMD.43-45,68-73 Conversely, a moderate amount of research has focused on genotype and 
the discovery of genetic variants associated with AMD. An even smaller amount of research has 
analyzed the effects of L/Z on the expression of genes involved in AMD. This chapter will 
highlight gaps in genotype and gene expression studies, where further investigation is needed. 
 
6.1 Future Directions for Genotype Studies 
 
Future investigation into genotype should focus on employing GWAS studies to identify 
variants in other AMD-related genes. In this review, three genetic variants related to HDL status 
were identified by GWAS studies. Figure 23 describes other genetic variants, associating L/Z 
status with AMD, which have been identified by candidate gene studies. Aside from HDL 
status74, there are three groups of genes that may influence L/Z response and AMD risk, 
including: 1) genes related to L/Z membrane transport, 2) genes related to carotenoid cleavage, 
and 3) genes previously related to age-related maculopathies. Variants in genes related to the 
transport of L/Z across cell membranes include CD36, GSTP1, and ApoE.75-79 Variants in genes 
related to carotenoid cleavage that may affect retinal uptake of L/Z include BCMO1, BCO2, and 
RPE65.60,77-81 Variants in genes previously associated with age-related maculopathies such as 
Sorby's fundus dystrophy and Sjorgren-Larsson Syndrome include TIMP355 and ALDH3A278,79, 
respectively. These genes should be further examined in order to understand which genetic 
variants confer the greatest risk of developing AMD. 
 
  
 
 
 
 
 
 
 
  
  
Figure 23. Genotypes that are important to L/Z status and AMD pathogenesis. These genes were 
identified by candidate gene studies and should be further examined in order to understand their 
effects on development of AMD.  
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However, candidate gene studies have less stringent statistical power than GWAS 
studies. Thus, candidate gene studies may reveal false-positive associations. Moving forward, a 
GWAS approach should be used to determine if the genetic variants identified by candidate gene 
studies truly have a significant impact on the relationship between L/Z and AMD. 
At the same time, GWAS studies should also be performed in different ethnic groups 
residing in different geographical locations. The genotypes investigated in this review reported 
significant associations between HDL-related variants and AMD for Caucasian cohorts in the US. 
However, specific genetic backgrounds related to ethnicity may or may not reveal these same 
associations. It is therefore necessary to perform GWAS in various racial groups. Doing so will 
determine if the results of genotyping, an important part of personalized medicine, can be 
generalized and effectively applied to a diverse patient base. 
In the context of personalized nutrition, genotyping for other AMD-susceptibility alleles 
is important for determining which patients are at the greatest risk for AMD. Figure 24 depicts 
how genotyping fits into the concept of personalized nutrition. Variants in genes related to L/Z 
membrane transport, carotenoid cleavage enzymes, and known age-related maculopathies may all 
influence the body’s response to L/Z. Given that AMD is a complex polygenic disease, data for 
all genetic variants related to L/Z response and AMD risk is needed in order to make the most 
effective dietary recommendations.  
 
 
Figure 24. Personalized nutrition: Further investigation into other AMD-susceptibility alleles. 
Genetic variants related to L/Z membrane transport, carotenoid cleavage, and age-related 
maculopathies may confer higher risk for AMD.  
 
6.2 Future Directions for Gene Expression Studies 
 
Future investigation into gene expression should focus on in vivo studies, the effects of Z, 
and alternative pathways involved in AMD pathogenesis. The particular genes included in this 
review were all proinflammatory genes down-regulated by treating LPS-induced RAW264.7 cells 
with L. The next step is to test the protective effect of L in vivo using mouse models. 
Additionally, the potentially protective effects of Z should be investigated both in vitro 
and in vivo. As shown in Figure 25, it has been suggested that Z may up-regulate antioxidant 
genes via the Nrf2 pathway.82 According to a study published by Zou in 2014, Z was found to 
activate the Nrf2/Keap1 pathway in ARPE-19 cells. Similar to the NF-κB pathway, Z disrupts the 
binding between Nrf2 and cytosolic Keap1, freeing Nrf2 to translocate into the nucleus. Nrf2 
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binds to DNA and upregulates the transcription of antioxidant phase II enzymes (HO-1, NQO-1, 
GCLc, and GCLm). Overall, Z increases the antioxidative capacity of RPE cells by inducing the 
protective Nrf2 pathway, inhibiting AMD pathogenesis. Thus, Z’s role in the antioxidant 
response and its underlying mechanisms require further investigation. 
 
Figure 25. Adapted from Zou.82 Zeaxanthin’s (Z) possible antioxidant effect. Z may upregulate 
the antioxidant response, protecting against the development of AMD.  
 
In the context of personalized nutrition, genetic information that reveals differential 
expression of antioxidant genes can be used to create personalized nutritional recommendations 
that most effectively delay AMD. Figure 26 depicts how genetic information concerning gene 
expression fits into the concept of personalized nutrition. Individuals with lower expression of 
Nrf2-dependent antioxidant genes may require higher levels of Z. Greater understanding of both 
L’s effect on inflammatory genes in vivo and Z’s effect on the antioxidant response are needed to 
pinpoint the most beneficial level of L/Z intake for individual patients. 
 
Figure 26. Personalized nutrition: Further investigation into antioxidant genes. Individuals with 
low Nrf2-dependent antioxidant responses may be at higher risk of AMD and require higher 
intakes of Z.  
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Chapter 7. Conclusions 
 
This review compiled primary literature investigating the interactions between dietary 
L/Z intake, genetic variation, gene expression, and advanced AMD. First, epidemiological studies 
showed that high dietary intake of L/Z may protect relatively younger people in the initial stages 
of AMD from progressing to the advanced stage of AMD. Secondly, first-degree relative studies 
and twin studies showed that there is a strong genetic basis to AMD. Thirdly, GWAS studies 
showed that certain genetic variants in HDL-related genes are associated with AMD risk, possibly 
by influencing the transport efficiency of L/Z in retinal cells. Fourthly, in vitro studies showed 
that L can protect against AMD by down-regulating proinflammatory genes via the NF-κB 
signaling pathway.  
A summary of the main findings are presented in Figure 27. A high intake of dietary L 
and/or Z was observed to correlate with lower risk of advanced AMD, possibly by protecting 
relatively younger persons (60-79 years) with early AMD against progression to the advanced 
stage. Certain genetic variants in HDL-associated genes were also suggested to correlate with 
lower risk of AMD, possibly by increasing the efficiency of L/Z uptake into retinal cells. Once 
inside retinal cells, L was shown to down-regulate the expression of proinflammatory genes and 
molecules, possibly inhibiting AMD pathogenesis.   
 
 
 
 
 
                
 
 
                        
 
Figure 27. A summary of the nutrigenomics of AMD. Overall, genotype and gene expression are 
key components of the mechanism by which dietary L/Z suppresses the development of advanced 
AMD. 
 
Altogether, the research indicates that increasing dietary L/Z intake may be an effective 
protective strategy to avoid a large increase in cases of advanced AMD. Since specific genetic 
variants confer differential risk to AMD, genomic testing can pinpoint the most effective levels of 
dietary intake. Clinically, genetic information should be used to personalize dietary 
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recommendations to delay progression of advanced AMD. To advance the field of eye care, a 
personalized nutrition approach should be pursued as the next protective strategy against eye 
disease.   
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Appendix A 
Acronyms and Abbreviations 
 
ABCA1 ATP-Binding Cassette Subfamily A Member 1  
Akt  Protein Kinase B 
ALDH3A2 Aldehyde Dehydrogenase 3 Family Member A2 
AMD  Age-Related Macular Degeneration 
ApoE  Apoliproprotein E  
AREDS Age-Related Eye Disease Study 
AREDS2 Age-Related Eye Disease Study 2 
BCMO1 Beta-Carotene 15,15'-Monooxygenase 1 
BCO2  Beta-Carotene Oxygenase 2  
BMES  Blue Mountains Eye Study  
CD36  Cluster of Differentiation 36  
CETP  Cholesteryl Ester Transfer Protein  
ChIP  Chromatin Immunoprecipitation  
CNV  Choroidal Neovascularization  
COX-2  Cyclooxygenase 2 
DNA  Deoxyribonucleic Acid 
DZ  Dizygotic 
EDCCS Eye Disease Case-Control Study 
ELISA  Enzyme-Linked Immunosorbent Assay 
EMSA  Electrophoretic Gel Mobility Shift Assay 
FFQ  Food-Frequency Questionnaire  
GCLc  Glutamate-Cysteine Ligase Catalytic Subunit 
GCLm  Glutamate-Cysteine Ligase Modifier Subunit 
GSTP1  Glutathione S-Transferase Pi 1 
GWAS  Genome-Wide Association Study 
H2O2  Hydrogen Peroxide  
HDL  High-Density Lipoprotein 
HO-1  Heme Oxygenase 1  
HPFS  Health Professionals Follow-Up Study  
IKK  Inhibitor of Nuclear Factor Kappa-B Kinase 
iNOS  Inducible Nitric Oxide Synthase 
Keap1  Kelch-Like ECH-Associated Protein 1 
LIPC  Hepatic Lipase 
LPS  Lipopolysaccharide 
mRNA  Messenger Ribonucleic Acid  
MZ  Monozygotic 
NF-κB  Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells 
NHANES III Third National Health and Nutrition Examination Survey  
NHS  Nurses' Health Study  
NIK  Nuclear Factor-Kappa-B-Inducing Kinase 
NQO-1  NAD(P)H Quinone Dehydrogenase 1 
Nrf2  Nuclear Factor (Erythroid-2)-Like 2  
NO  Nitric Oxide 
O2-  Superoxide Anion  
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1O2  Singlet Oxygen  
OH•  Hydroxyl Radical  
OR  Odds Ratio 
PGE2  Prostaglandin E2 
PI3K  Phosphoinositide 3-Kinase 
PTEN  Phosphatase and Tensin Homolog 
RAW264.7 A Mouse Macrophage Cell Line 
RNA  Ribonucleic Acid  
ROS  Reactive Oxygen Species  
RPE  Retinal Pigment Epithelium 
RPE65  Retinoid Isomerohydrolase  
RR  Risk Ratio or Relative Risk 
RT-PCR Reverse Transcription-Polymerase Chain Reaction 
SNP  Single Nucleotide Polymorphism 
TIMP3  Tissue-Inhibitor of Metalloproteinase 3  
UK  United Kingdom 
US  United States 
USDA  United States Department of Agriculture  
VEGF  Vascular Endothelial Growth Factor 
VLDL  Very Low-Density Lipoprotein 
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